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ABSTRACT
Clostridium difficile infection (CDI) is a major hospital-acquired diarrhea that can
cause life-threatening complications such as pseudomembranous colitis. CDI is caused by
colonization of host with C. difficile, a Gram positive, anaerobic bacterium known to
produce toxins that cause disease. Normally, the gut microbiota protects the host from
CDI, but disruption of the microbial composition through antibiotic treatment can leave
one vulnerable for CDI. To date, no vaccines for preventing CDI are available.
In this study, the potential of antibodies directed against specific surface
molecules of C. difficile to block bacterial adherence to host gut epithelial cells was
studied, in hopes for developing a vaccine that could prevent colonization and disease.
Antibodies against recombinant FliD (flagellar cap protein), HMW SLP (surfaceassociated protein), and Cwp84 (cysteine protease) were generated in rabbits and tested
for their ability to reduce C. difficile adherence to Caco-2 BBE cells, a human colonderived epithelial cell line. In this model, the antibodies against target molecules did not
significantly decrease C. difficile adherence, although the target molecules had been
found to be adhesins in the literature using other models. Thus, these data suggest that
blocking of C. difficile adherence to epithelial cells using antibodies against adherenceassociated surface molecules may be assay-dependent, highlighting a need to develop
other models that can effectively simulate the in vivo conditions of CDI pathogenesis.
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CHAPTER ONE
REVIEW OF LITERATURE
Introduction
Clostridium difficile (C. difficile) is a Gram positive, anaerobic bacterium that
causes diarrhea and in severe cases, pseudomembranous colitis1. C. difficile is able to
form spores that are extremely durable and can contaminate various surfaces including
those within healthcare environments2. The spores can be ingested by people coming in
contact with the spore-contaminating surfaces, and the bacteria can then colonize the gut
if the intestinal microbiota is already disrupted3. Since antibiotics, the treatment of choice
for a variety of bacterial infectious diseases in modern medicine, cause disruptions in the
composition of the host microbiota, people undergoing antibiotic therapy are often at
increased risk for C. difficile infection (CDI)4. Since the use of antibiotics is common in
various healthcare settings today, many of the CDI cases are known to be healthcareassociated5. Although the major risk factor for contracting CDI is the use of antibiotics,
the latest treatment recommendation for CDI is still antibiotic therapy using
metronidazole or oral vancomycin in severe cases6. Consequently, a major problem with
CDI is that about 12-25% of patients undergoing CDI treatment suffer from recurrent
disease when treatment is stopped3. Thus, novel approaches to treat CDI are needed.
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Several new approaches for treating CDI have been described, and this includes
three broad approaches: antibiotic agents with higher specificity to C. difficile spare the
normal microbiota7, biotherapeutic agents8, 9, 10, and vaccines11, 12, 13. In the case of
vaccine development, the primary goal in the field has been to induce an anti-toxin
immune response, as CDI is known to be a toxin-mediated disease. Some of these
vaccines that target the toxins are currently undergoing clinical trials12, 13. However, an
anti-toxin immune response is not likely to prevent colonization of patients with C.
difficile, as many protected individuals that develop anti-toxin antibody responses can
still shed spores into the environment and contaminate their surroundings. From an
epidemiological standpoint, a vaccine that prevents colonization of patients and thus
prevents the transmission of infective spores would be more ideal for containing the
disease’s spread. Still, developing such a vaccine is a challenging process due to the
complex nature of C. difficile colonization of the human host that is yet to be fully
understood. Studies need to be conducted to identify target antigens and their ideal
formulations in order to develop vaccines that prevent colonization.
This study aims to test the possibility of blocking C. difficile adherence to human
gut epithelial cells, in order to identify candidate antigens and formulations for novel
vaccine development that can prevent colonization. Bacterial adherence is thought to be
an important part of colonization process. Thus, if a vaccine formulation could block
adherence in an immunized host, it could prevent colonization. Antibodies against such
antigen should block adherence of the bacteria to gut epithelial cells in vitro. If not, a
different formulation may be needed for effective vaccines. Three candidate molecules of
C. difficile, HMW SLP, Cwp84, and FliD, are tested in this study to determine if
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antibodies against these molecules can inhibit C. difficile adherence to Caco-2 BBE cells,
a human colonic epithelial cell line.

Clostridium difficile Infections
C. difficile, first identified in stool samples from infants and formerly known as
Bacillus difficilis14, is a Gram positive anaerobe that is known to be one etiological agent
of antibiotic-associated diarrhea (AAD)15. C. difficile produces two major toxins, toxin A
(TcdA) and toxin B (TcdB), both of which are known to damage the gut mucosal barrier
function through the disruption of the intracellular cytoskeletal network16, 17. The
disruption of the gut mucosal barrier function leads to the recruitment of inflammatory
cells to the site of damage and the patients subsequently suffer from diarrheal disease18.
The traditional treatment for CDI, and the current one for mild cases, has been simply the
stoppage of current antibiotic therapy until diarrhea resolves6. Unfortunately, the cases of
CDI, based on hospital discharge diagnoses, increased in prevalence and also in disease
severity between 1993 and 200519, 20. Now, the rate of nosocomial (hospital-acquired)
CDI has increased to the point that it rivals methicillin-resistant Staphylococcus aureus
(MRSA) infections21, and currently accounts for 20-30% of all cases of healthcareassociated diarrhea6.
The explanation for the recent increase in the rate of CDI appears to be
multifactorial. One major factor is the widespread use of antibiotics. It is known that use
of antibiotics is a major risk factor for CDI4, supported by the fact that about 95% of the
cases of CDI are healthcare-associated; patients who develop CDI typically have
exposure to healthcare facility or service5. Another factor to be considered is the
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emergence of hypervirulent strains of C. difficile. One prominent hypervirulent strain is
known as BI, NAP1, or 027, depending on the method in which they were typed; there
are other strains that are also considered hypervirulent but the BI group is the most
common.
Compared to strain 630, the most well characterized strain of C. difficile to date,
the hypervirulent BI strains are noted for their resistance to fluoroquinolones and a
deletion in tcdC gene22; TcdC is thought to regulate the expression of tcdA and tcdB
which code for the two major toxins of C. difficile23. The mechanism by which the
change in TcdC expression in this strain contributes to hypervirulence is unclear24 as
association of the mutation to actual disease severity has not been established25. Rather,
factors contributing to the regulation of toxin production are very complex, as it has been
demonstrated that toxin production is also linked to flagellar regulation26, 27 and response
to environmental stress such as antibiotic exposure28. It is, however, clear that the
severity and mortality rates of CDI have increased following the emergence of the
hypervirulent strains, and many more cases today require measures beyond traditional
methods to deal with CDI such as vancomycin6; in very severe cases, surgical removal of
inflamed colon is performed.
A challenging issue that clinicians face today is recurrent CDI following
treatment. Most CDI patients resolve their diarrhea and disease symptoms upon
treatment.. However, after treatment is stopped, about 12-25% of patients experience
disease relapse3; these recurring patients can experience multiple episodes of CDI, each
after a course of CDI treatment. Repeated treatments and the added problem of serious
complications requiring surgery have put a heavy financial burden on the healthcare
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system, estimated to be $500 million annually in the United States ; another study
estimates the cost to be over $3 billion113. Antibiotics are the treatment of choice when it
comes to managing CDI. Currently, physicians try to manage disease recurrence with
tapering antibiotic regimen, where the frequency of each antibiotic dosage is decreased
over time3. However, antibiotics used for CDI treatment are also risk factors for CDI4, as
they also disrupt the normal microbiota which prevents host colonization with C. difficile.
Animal models of CDI, traditionally using hamsters30 and more recently mice31,
utilize antibiotic treatment followed by administration of infectious dose of C. difficile
spores to induce disease. In these models, antibiotic administration is thought to disrupt
the microbiota colonizing the intestine, leaving the animals permissive for C. difficile
colonization. It has been demonstrated that a single dose of clindamycin, an antibiotic
historically linked to CDI, causes significant alterations to the gut microbiota, leaving
mice susceptible to CDI32. Likewise, another mouse model for CDI administers
metronidazole and vancomycin to mice prior to C. difficile spore challenge31; these are
the same drugs currently recommended for treatment of CDI patients. Thus, treatment of
CDI puts some patients at increased risk for CDI, and when more contaminating C.
difficile are ingested while at risk33 or persisting C. difficile grow, the patients can
contract CDI again. This cycle of CDI recurrence is illustrated in Figure 1; patients
undergo antibiotic therapy for CDI which can lead to subsequent CDI recurrence, and the
disease cycle continues until successful therapy leads to a cure. To break such a
destructive cycle, a novel approach to treating or preventing CDI is urgently needed.
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Figure 1. Schematic diagram of CDI recurrence cycle. Antibiotic treatment leads to CDI
which can be cured once antibiotic treatment is stopped. In some cases, CDI is treated
using antibiotics. While this can cure CDI, it also puts one at risk for CDI. Thus, a
destructive cycle of recurrent CDI can occur. ABX: antibiotics. Black Arrow: nonrecurrence disease pathway. Red Arrow: recurrent disease pathway.
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Novel CDI Therapeutics
Looking at the rate of recurrent disease, and the financial burden it puts on the
healthcare industry from repeated treatment regimen and severe complications, standard
antibiotic therapy for CDI is becoming less effective. In response, there are many novel
approaches to CDI treatment in development today. These new approaches can be
classified into three groups: antimicrobial therapy, biotherapeutics, and immunologic
therapy.
Currently, there are some novel antibiotic compounds tested to improve CDI
treatment effects compared to vancomycin34. One of the novel antimicrobial therapeutic
agents is called fidaxomicin, an antibiotic agent recently approved by the Food and Drug
Administration (FDA) for the treatment of CDI. During clinical trials, this drug was
shown to be equivalent to vancomycin, but a lower rate of recurrence was achieved
compared to vancomycin in clinical trials35. A possible advantage of fidaxomicin is that,
compared to standard antibiotics for CDI, the drug is more specific for C. difficile; the
microbiota isolated from stool samples from patients undergoing fidaxomicin therapy
was altered to a lesser degree compared to samples from patients undergoing vancomycin
therapy36. Fidaxomicin may lessen the risk for CDI recurrence by having a lesser impact
on the microbiota compared to standard treatment options. This suggests that the increase
in antibiotic specificity can lead to a better treatment for CDI that decreases the risk of
recurrence.
Knowing about the importance of normal microbiota in CDI, treatment
approaches using probiotics have been studied extensively. An alternative therapy that
has shown success in treating CDI is fecal transplantation. This therapy seeks to restore
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the balance in the microbiota of CDI patients, whose microbiota has been disrupted by
antibiotic use and subsequent infection with C. difficile. The human gastrointestinal tract
houses a large population of microbes consisting of fungi, viruses, archaea, small
eukaryotes, and bacteria. These intestinal symbionts play a crucial role in the
maintenance of human health, as the microbiota are involved in development and
modulation of the host immune system37, 38, 39, 40, host metabolic processes41, and
protection from pathogens42, 43. In the case of CDI, the normal microbiota seems to confer
colonization resistance against C. difficile, as antibiotic administration alters the
microbiota to confer susceptibility to CDI32. Fecal transplantation transfers microbiota
from a healthy donor to a CDI patient whose microbiota is altered, and thus colonization
resistance is established in the CDI patient. This therapy has shown success, including a
recent clinical trial showed greater success with fecal transplants when compared to
standard vancomycin therapy in curing CDI and in limiting recurrence10. While the
therapy is effective, the specific effector organisms in fecal transplantation involved in
protection from CDI have not been identified, not to mention that many have never been
successfully cultured for study before. As studies continue, the microbes needed to
induce colonization resistance against C. difficile will be identified and lead to specific
probiotic therapeutics in the near future.
Immunologic therapy for CDI has been under study for more than twenty years44;
a vaccine for CDI was studied in hamsters using formalin-inactivated C. difficile cells and
culture filtrates in 199545. Since CDI is mediated by the two major toxins, vaccines
targeting these toxins as antigens remain the best studied so far. The development of antitoxin antibody response is suggested to be protective against disease symptoms, since

9
asymptomatic carriers have increased levels of anti-TcdA IgG serum antibodies
compared to symptomatic patients46. Also, human monoclonal antibodies (mAb) against
toxins have been shown to protect hamsters from lethal C. difficile challenge47, and to
reduce the rate CDI recurrence among patients given toxin-specific mAb48. The most
promising vaccine target currently seems to be a fusion protein of TcdA and TcdB
receptor binding domains that was shown to be effective in a mouse model49; targeting
both toxins is preferred because the relative importance of TcdA versus TcdB in disease
is not entirely clear (strains expressing either both toxins or TcdB only can all cause
disease). Meanwhile, it has been shown that a toxin B targeting vaccine does not prevent
C. difficile colonization in hamsters while it does protect the animals from disease when
challenged with a strain only producing TcdB11. Because toxins are not assumed to be
involved in the initial colonization process, vaccines targeting the toxins would not likely
prevent colonization in patients whose intestinal microbiota is disrupted. Thus, a
successful toxin-based CDI vaccine may result in asymptomatic carriage and subsequent
spread of infectious spores to the environment including hospital surfaces. In order to
design a vaccine that prevents colonization and subsequent CDI, this study aims to test
candidate adhesins of C. difficile to determine if antibodies against chosen molecules
could block adherence. Such a vaccine, by preventing adherence and subsequently
colonization, could prevent disease and its spread.

10

Therapy

Examples

Potential Cost

Microbiotasparing ABX

Fidaxomicin

High

Biotherapeutics

B. coagulans, Lactobacilli, Fecal
transplantation, Non-toxigenic C.
difficile

Low

mAb

High

Vaccines

Likely low

Immunologics

Table 1. Summary of developing therapeutics for CDI and potential cost estimate of each
category.
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Candidate Molecules for Vaccine Development
Bacterial flagella are recognized to be virulence factors in many different
pathogens, serving a variety of functions including role in motility50. In particular, FliD,
the capping protein for the flagellar apparatus in many bacteria, has been demonstrated to
play a role in colonization of mammalian hosts in different bacteria51, 52. In the case of C.
difficile, FliC is the flagellin subunit that makes up the fibrous portion of the flagella,
while FliD serves as the capping protein at the outer tip of the flagellar structure, as
illustrated in Figure 2. Both FliC and FliD have been shown to bind to mucin, a protein
component of intestinal mucus, and FliD has also been found to bind to epithelial cells in
vitro53. The in vivo significance of FliD in colonization and disease is not clear, as studies
with a mutant unable to produce FliD found the mutant to have enhanced virulence26; this
is inconsistent with the previous finding that flagellated strains tend to have increased
adherence compared to non-flagellated strains within the same serogroup53. However,
this increase in virulence may be a byproduct of mutagenesis itself, as toxin production
was found to be increased in fliD mutants26; the regulation of toxin production was found
to be partly related to flagellar regulation27. While both FliC and FliD seem to be
involved in the colonization process, it was shown that CDI patients tend to generate
more antibodies against FliD than FliC54. FliC has been shown to have variability in
DNA restriction fragment length polymorphism (RFLP) patterns and in protein sequence
amongst different serogroups of C. difficile55, meaning there is limited antibody crossreactivity for FliC among C. difficile strains. In contrast, antibodies produced against
FliD of one serotype cross-reacts with FliD from other serotypes56. This can make FliD a
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good vaccination target as the immune response generated by this molecule likely will be
directed against multiple strains and thus confer protection against multiple strains.

13

Figure 2. Illustration of C. difficile cell with a flagellar structure. FliC is the flagellin
subunit while FliD is the capping protein. The flagellar fiber is attached to a flagellar base
apparatus on the cell. C. difficile is known to express multiple flagellar fibers, but only
one is illustrated in this figure.
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C. difficile, like many other bacteria, has a protein array that covers the surface of
the cell in close association with its cell surface57. The proteins, termed surface layer
proteins (SLPs), serve a variety of functions including protective coating, adhesion, ion
trapping, cell shaping, and cell division in a variety of different organisms of both
bacteria and archaea58. Although the sequence and structure of SLPs are very diverse
amongst different species, SLPs have co-evolved to share some properties such as selfassembly, regularity of pores, and association with the underlying cell surface structure58.
In C. difficile, the SLP monomers are made of two subunits of different size, termed lowmolecular weight (LMW) and high-molecular weight (HMW) SLP57. These proteins are
encoded by slpA gene which translates into a precursor protein that is cleaved by
proteolysis into the two subunits59. The subunits then form a stable complex that serves
as the monomer to subsequent S-layer self-assembly as illustrated in Figure 360. One
suggested function of the SLPs in C. difficile is adhesion to host intestinal mucosa, as the
proteins were found to be associated with colonic sections of both humans and mice upon
co-incubation with tissue samples; SLPs were also shown to interfere with C. difficile
adhesion to HEp-2 cells61, an epithelial cell line derived from HeLa cell contaminants62.
Thus, SLPs seem to be a good target for vaccine development since they are associated
with adhesion process and covers the entire cell surface. Also, the proteins form an array
of identical subunits, which likely makes them good immunogens. The structural studies
indicate that LMW SLP is more surface exposed60 and likely more immunodominant.
However, LMW SLP shows high antigenic diversity among the different strains of C.
difficile and such, a vaccine may confer protection against only a few strains59.
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Figure 3. Illustration of C. difficile cell wall structure with overlaying S-layer. A. The
plasma membrane is covered with a thick peptidoglycan layer characteristic of a Gram
positive organism. The SLP paracrystalline layer is closely associated with the
peptidoglycan layer through conserved domains in HMW SLP. Other cell wall proteins
are incorporated into the S-layer. B. Illustration of the SlpA, the precursor molecule for
the SLPs. The triangles denote proteolytic cleavage sites in the maturation process. SlpA
does contain a signal peptide (left-most portion of SlpA in B) believed to be involved in
the secretion pathway for the molecule. Figure from Fagan et al. 2009. Molecular
Microbiology60.
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In contrast, HMW SLP is less exposed to the host immune system to recognize
and is thought to be localized more towards the interior part of the S-layer due to its
interactions with the underlying cell wall60. Despite the localization, HMW SLP was
found to be an immunoreactive cell wall protein in sera of CDI patients63, indicating that
the antigen can be exposed to the host immune system. The HMW SLP is more
conserved amongst different strains of C. difficile, since it must have domains that
interact with the Gram positive peptidoglycan layer. Indeed, antibodies raised against
HMW SLP of strain 630 cross-reacts with HMW SLP of other strains including toxigenic
and non-toxigenic strains59. Thus, in contrast to LMW SLP, a vaccine targeting HMW
SLP could confer protection from many different strains of C. difficile.
As illustrated in Figure 3, the S-layer of C. difficile does contain various other
molecules. Many of these proteins are paralogs of SlpA called cell wall proteins (Cwp),
as they share three putative cell wall binding repeat 2 (Pfam 04122) domains to interact
with the underlying cell wall64. Each paralog has its own unique domain that may provide
a variety of different functions65. One particular Cwp of interest is Cwp84, a cysteine
protease known to be responsible for the proteolytic cleavage of SlpA into the LMW and
HMW SLP subunits66, 67. This processing of SlpA is critical for the generation of a proper
S-layer, since insertional disruption of cwp84 gene expression results in cell wall proteins
and SlpA being found in the culture supernatant, indicating poor incorporation of the
proteins into the S-layer68, 69. Multiple forms of Cwp84 are known to exist during its
maturation process, but which form or forms, under in vivo conditions, cleaves SlpA is
not yet clear69. Other than the cleavage of SlpA, Cwp84 protease function extends to
many other targets including host extracellular matrix proteins70. Precisely what the in
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vivo role of degrading extracellular matrix proteins serves for C. difficile pathogenesis is
unclear. While the question of whether an antibody response directed against Cwp84 is
protective is unknown for humans, some patients do make antibodies against Cwp8463,
and Cwp84 has been tested in active immunization of mice for protection along with
FliD71,72. Perhaps an antibody response could interfere with the incorporation of Cwp84
into the S-layer during its assembly or affect the protein in a way the function can be
blocked. This study is designed to test whether antibodies against Cwp84 could alter C.
difficile adherence in vitro.

Other Virulence Factors
Studies of C. difficile adhesion interference in the literature have always reported
partial decreases in adherence61, 73, and vaccination studies of animals, while they have
suggested protection, have not demonstrated complete clearance of pathogen from the
animal71, 74. This suggests that C. difficile utilizes many different molecules and pathways
in its colonization process of the host. Studies of C. difficile proteins have been difficult
due to the lack of genetic tools to generate mutants. However, a new system utilizing
homologous insertion with bacterial conjugation, named ClosTron75, has allowed for the
generation of functional knockouts in C. difficile and study of specific molecules became
more available. Many different factors for colonization in addition to the ones listed in
the previous section have been previously described, and many hold therapeutic potential
for CDI.
One of the earliest discovered adhesin for C. difficile was Cwp66, a SlpA paralog
like Cwp84. The study of Cwp66 revealed that antibodies against Cwp66 inhibited C.
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difficile adhesion to Vero cells, a monkey kidney epithelial cell line . An interesting
aspect of Cwp66 is that it is not present at the cell surface under normal culture
conditions, but upon heat-shock at 60°C for twenty minutes, Cwp66 localizes to the cell
surface, perhaps to the S-layer since the protein is a SlpA paralog. Also, the antibodymediated adhesion interference with Cwp66 was limited to the heat-shocked C. difficile
with antibodies against Cwp66 from heat-shocked bacteria76. It was subsequently found
that Cwp66 has distinct antigenic properties after heat-shock, as antibodies against
normal Cwp66 did not recognize the heat-shock induced Cwp66 and vice versa76. Thus, it
is not clear yet how Cwp66 actually may mediate adhesion in vivo, and the question of
Cwp66 as a potential vaccine antigen remains open.
Another heat-shock protein identified to have a role in C. difficile adhesion is
GroEL (or heat-shock protein 60, Hsp60). In heat-shocked C. difficile, GroEL was found
to be localized to the cell surface and recombinant GroEL or antibodies against GroEL
both inhibited adherence of heat-shocked C. difficile77. However, GroEL lacks the signal
peptide normally present in bacterial molecules that localize to the cell surface, so how
GroEL may be exposed to antibodies in this case is unclear. Seeing that many
environmental stress factors such as high acidity, high osmolarity, iron deficiency, and
heat stress modulate adherence in C. difficile78, that transcription of genes from the
pathogenicity locus that codes for TcdA and TcdB increases during later phases of
growth in culture when nutrients are relatively scarce79, and that many other virulence
genes are upregulated under stress conditions like high salt concentration and
subinhibitory antibiotic dose in culture80, there may be an association between C. difficile
virulence and environmental stress the bacteria face. Although it is unknown if an
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immune response against stress-induced molecules including GroEL would be able to
protect from CDI since the expression profile of these molecules is unknown in in vivo
conditions, it may still be a feasible approach to target stress-related molecules for
vaccine development to prevent C. difficile colonization.
It has been thought that C. difficile adheres to the brush border components of the
intestine since the bacteria were observed to be associated with the apical tip of the brush
borders of Caco-2 cells, a human intestinal cell line derived from a colon carcinoma. Also,
it was also shown that the increase in brush borders, through spontaneous differentiation
of Caco-2 cells in culture, seemed to increase the level of adherencce81. However, it was
demonstrated that treatment of Caco-2 cells with calcium ion (Ca2+) chelators such as
ethylene glycol tetraacetic acid (EGTA) to expose the basolateral side of the Caco-2
through the disruption of the intercellular junctions increases adherence of C. difficile,
and that C. difficile seems to associate with projections that look like extracellular matrix
(ECM) components when observed by scanning electron microscopy (SEM); it was
confirmed that the bacteria can bind to immobilized ECM proteins82, suggesting that C.
difficile can bind to ECM proteins for adherence to Caco-2 cells.
Fibronectin is a ubiquitous protein of about 440kD that is a major part of the
ECM that supports various tissues83. It is known that Streptococcus pneumoniae (S.
pneumoniae) and Streptococcus pyogenes (S. pyogenes) bind to fibronectin84, 85, and that
this process seems to be mediated by fibronectin-binding proteins (Fbp)86. C. difficile also
possesses FbpA (noted FbpA in strain 630 and Fbp68 in strain 79-685) that mediates C.
difficile binding to immobilized fibronectin87 in manganese (Mn2+) dependent manner88.
Although anti-Fbp68 antibodies showed interference of C. difficile adherence to Vero
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cells , suggesting that Fbp68 may mediate adherence to epithelial cells, disruption
mutants of fbpA (ΔfbpA) showed increase in adherence to Caco-2 and HT29-MTX
(mucus producing human intestinal epithelial cell line)89, suggesting that the role FbpA
plays in overall C. difficile adherence remains to be understood. Still, the same study
demonstrated that the ΔfbpA mutant poorly colonized mice in two of three models of
differing intestinal microbiota compared to wild-type C. difficile89, and the bacteria
possesses Cwp84 which can exert proteolytic functions against ECM proteins70,
suggesting that C. difficile interaction with ECM proteins like fibronectin may still be
important in the overall colonization process.
The emergence of hypervirulent strains of C. difficile has compounded the
challenge for clinicians to treat CDI. One feature of the BI group (by restriction
endonuclease analysis (REA) typing and 027 by polymerase chain reaction (PCR)
ribotyping), one of the hypervirulent strains, is the production of binary toxin (CDT) in
addition to TcdA and TcdB. CDT is an actin-specific adenine diphosphate (ADP)ribosyltransferase that has cytotoxic effects in Vero cells that can be neutralized by
antibodies against Clostridium perfringens (C. perfringens) iota toxin90. CDT is a
member of iota-family binary toxins present among many different species of
Clostridia91. The iota family binary toxin functions are known to be mediated in part by
CD44 on host cell surface that serve a variety of functions in different cells92, as CD44-/cells are known to be resistant to the cytotoxic effects of these toxins93. Also, lipolysisstimulated lipoprotein receptors (LSR) seem to be important for CDT uptake since CDT
can induce clustering of LSRs into lipid rafts94, a possible mechanism for subsequent
signaling. Other than cytotoxic effects in some cell lines, an interesting function that
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CDT has is the effect on microtubular network in Caco-2 cells, where the treatment of
Caco-2 cells with CDT induced microtubule-based thin projections from the host cell
surface that formed a net that seemed to trap C. difficile, and this indeed correlated with
increased adhesion; this process was demonstrated to also be neutralized by treatment
with anti-iota toxin antibodies95. While it can be assumed that the production of binary
toxin by the hypervirulent strains could help the C. difficile to adhere better to intestinal
epithelium via this microtubule extension mechanism, further studies are needed to see if
the production of binary toxin indeed contributes to colonization and subsequent disease.

Biofilms and Spores
Many bacteria form a biofilm, a complex structure consisting of specialized
microbial communities, polysaccharides, and other compounds96. These community
structures can form on many different surfaces including biological surfaces like the
gastrointestinal epithelium. Biofilms provide the microbial community many
characteristics such as resistance to antimicrobial compounds and resistance to sheer
forces96. It is thought that a freely moving, planktonic bacterium comes in contact with a
surface to which the bacterium first associates with then adheres to. At certain point, the
bacteria start to produce extracellular material in which the colony becomes encased.
Subsequently, signals are produced to differentiate cells within the biofilm structure and
more matrix components are produced. Fragments of biofilm can become detached from
the biofilm structure and cells are dispersed. The general process of bacterial biofilm
development is illustrated in Figure 4.
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Figure 4. Illustration of bacterial biofilm formation. A. Free-swimming, planktonic
bacterium comes in contact with intestinal epithelial surface. Adherence to surface
usually induces downregulation of mobility-associated gene expression. B. Adherence
bacteria grow and form a colony. Colony starts to produce extracellular components. C.
Community of bacteria is now encased in thick extracellular matrix which serves a
variety of functions including resistance to antimicrobial compounds. D. Certain factors,
such as strong sheer forces can induce dispersal of new planktonic bacteria or even a part
of biofilm matrix containing matrix components and bacterial cells to be released to
spread elsewhere. Based on Hall-Stoodley et al. 2004. Nature Reviews Microbiology.
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C. difficile has also been demonstrated to form biofilms, especially when cocultured with certain bacteria97. It was also determined that biofilm formation by C.
difficile in vitro requires cwp84, spo0A, and luxS gene expression since the insertional
disruption mutants of each gene did not form biofilms98. This suggests that proper S-layer
processing, sporulation, and quorum sensing are required for biofilm formation,
respectively. It is interesting to note that spo0A, whose protein product Spo0A is known
to be the master regulator of sporulation that determines cell fate to become a spore in
Bacillus subtilis (B. subtilis)99 and C. difficile100, is required for biofilm formation. The
authors of the C. difficile Spo0A study also found that defect in sporulation increases
TcdA and TcdB, increases virulence in the hypervirulent strain in mice, and decreases
transmission of CDI to other mice as fecal shedding was eliminated. This is interesting
because one speculated mechanism in which recurrence can occur is through persistence
of C. difficile in the patient gastrointestinal (GI) tract which may be mediated in part by
resistant biofilm formation. The persisting C. difficile could then grow again while the
intestinal microbiota is still depleted following antibiotic treatment for CDI. If
sporulation is indeed a critical process for biofilm formation in vivo as suggested by in
vitro experiments, perhaps sporulation could be a target for novel therapeutics that could
alleviate disease recurrence. However, the degree to which biofilm formation actually
contributes to in vivo colonization is unknown, and further studies need to be done to
confirm that biofilm can be a target for preventive therapeutics for CDI.
Bacterial spores are a dormant form of the organism designed for prolonged
survival and resistance to a variety of environmental stresses. Thus, C. difficile is not
metabolically active and does not produce toxins while in the spore form; for CDI to
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occur, the spores must germinate and form vegetative cells. C. difficile spores are known
to adhere to surfaces such as semi-solid agar surface2 and the intestinal cell line Caco-2101.
While it may be that the spores of C. difficile likely can adhere to GI epithelium, the
extent to which such process contributes to overall colonization of the host is unknown. If
spores contribute in part to adherence and persistence of the organism in the host,
vaccines targeting spores or spore components may be a possible way to prevent CDI and
its recurrence.
There is an interesting surface protein on C. difficile S-layer known as CwpV.
CwpV is also a paralog of SlpA that contains a repeat domain unique to CwpV; this
domain seems to have antigenic variability amongst different strains102. Like many of the
SlpA paralogs, CwpV also undergoes maturation process through proteolytic cleavage, in
this case by autoproteolysis103. While variable amongst different strains, this protein does
seem to have a conserved function in promoting bacterial self-aggregation102. While the
in vivo significance of this function is still unknown, it can be speculated that this
function may be important in biofilm formation; it has been demonstrated in other
bacteria that autoaggregation seems to contribute to initial stages of biofilm formation104.
Interestingly, CwpV is known to be regulated at the transcriptional level by DNA
inversion mediated by specific recombinases, allowing for phase-variable expression105.
Although the expression of CwpV under in vivo settings is unknown, CwpV was
demonstrated to be the major Cwp within the S-layer when its recombinational
transcription switch is turned on102. Perhaps when the conditions are set for biofilm
formation, CwpV may be expressed within the S-layer to promote self-aggregation which
then may contribute towards biofilm formation. An antibody response that blocks this

25
autoaggregation function may affect biofilm formation. However, more studies are
needed to evaluate this possibility.
There are many molecules of C. difficile that have been identified to potentially
play a role in colonization of the host along with a variety of mechanisms of colonization.
Many of these molecules possess the potential for being targeted by vaccines to induce
protection in human hosts from CDI. The molecules described in this document are listed
in Table 2. In addition, there are certainly other molecules and mechanisms contributing
to host colonization and disease yet to be identified. Thus, the potential for developing
and improving a vaccine that could prevent CDI is vast.
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Virulence
Factor
TcdA/B
FliC
FliD

Description

Possible contribution to CDI

Major toxins
Flagellin subunit
Flagellar cap

SlpA

S-layer protein

Cwp84

Cysteine protease

Cwp13

Cysteine protease

Cwp66

Heat-shock adhesin

GroEL

Heat-shock protein

Disruption of host epithelium
Mucin binding
Mucin/Epithelial binding
Molecular exclusion, host
epithelial binding
SlpA processing
SlpA processing, Cwp84
processing
Adhesion to epithelium under
heat-shock
Protein refolding, adhesion
under heat-shock

FpbA/68
CbpA106
CdtA/B
Spo0A
CwpV

Fibronectin binding
protein
Collagen binding
protein
Binary toxin
Master regulator of
sporulation
Autoaggregation protein

ECM binding
ECM binding
Cytotoxicity, microtubular
trapping of bacteria for
enhanced adhesion
Sporulation, biofilm formation
Biofilm formation?

Table 2. List of C. difficile virulence factors, description of their function, and potential
contributions to disease.
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Mucosal Vaccines Targeting Colonization
The mucosal layer serves as the interface in which host and microbes interact, and
thus the host immune system is highly active at mucosal surfaces. A major component of
the mucosal immune system is secretory immunoglobulin A (sIgA). In the mucosa, sIgA
serves a variety of functions including prevention of bacteria adhesion107. As many
infectious agents initiate pathogenesis at this mucosal interface, developing a mucosal
immune response such as sIgA can prevent pathogenic processes from initiating and thus
protect the host from disease. However, the mechanism by which the sIgA (dimeric form
of IgA) response is generated is separate from the systemic antibody response that is
primarily IgG and monomeric IgA. As the transcytosis of immunoglobulins into the
mucosal layer is mediated by polymeric Ig receptor (pIgR), systemic antibodies generated
through systemic vaccine administration are thought not to cross into the mucosal surface.
In contrast, a mucosal vaccine would induce specific responses targeting to the mucosa
that would cross into the mucosal layer and function against mucosal pathogens. In
targeting microbial factors for colonization, such a mucosal response may prevent host
colonization with the target pathogen.
There are many vaccines that are designed to induce a mucosal immune response,
including vaccines for cholera, typhoid fever, rotavirus, influenza, and polio108. One
interesting vaccine in current use is the heptavalent pneumococcal conjugate vaccine
(PCV7). This vaccine consists of surface carbohydrates from different serotypes of
Streptococcus pneumoniae (S. pneumoniae) conjugated to diphtheria toxin. While this
vaccine is delivered systemically and not by a mucosal route, it was demonstrated that in
children vaccinated with PCV7, the S. pneumoniae colonizing the nasopharyngeal
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mucosa becomes seroconverted, where the strains of bacteria colonizing the vaccinated
children converts to non-vaccine strains109. This suggests that vaccination prevents
children from being colonized with vaccine-targeted strains S. pneumoniae. In the case of
C. difficile, toxin-targeting vaccines have been the focus of research, whereas studies to
develop vaccines that could prevent colonization have been few. One study measured the
level of C. difficile recovery from feces after challenging mice with or without
immunization with FliD, Cwp84, cell wall extract, flagellar preparation, or a combination
through various mucosal routes71. While the study demonstrated a slight decrease in C.
difficile recovery in immunized mice, the vaccine failed to prevent colonization. This
may have to do with the efficacy of the vaccination itself, since only the rectal
administration resulted in the production of antigen-specific IgA in the intestinal lavages
of mice while other routes had resulted in almost undetectable IgA levels. With the
uncertainty about the mechanisms behind C. difficile adhesion and colonization process,
further studies are still needed to develop a vaccine that can prevent colonization.
However, other mucosal vaccines already licensed for clinical use, and the success that
some vaccines have had in preventing colonization, suggest that prevention of CDI by
targeting colonization is possible.

Caco-2 BBE Colon Adenocarcinoma Cell Line
In order to test antibodies for their ability to interfere with C. difficile adherence, a
system modeling the gut epithelial surface has to be established. The Caco-2 cell line is
derived from human colon adenocarcinoma and is able to spontaneously differentiate and
polarize to have enterocyte-like qualities such as brush borders. Caco-2 brush border
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expressing clone (BBE) cells, derived from Caco-2 cells

110

, have been chosen as the

model for gut epithelial surface in this study. In the past, Caco-2 cell line has been used
in bacterial adherence assays under anaerobic conditions, which is crucial for the growth
and survival of vegetative cells of C. difficile. The Caco-2 survival was reported to be 98%
after three hours of incubation under anaerobic conditions111. Studies involving adhesion
interference in C. difficile have utilized mainly Vero cells53 and Hep-2 cells61, which can
bind enteric pathogens but are not of colonic origin. Thus, the Caco-2 BBE cell line has
been chosen since the cells are of colonic origin and express brush borders which C.
difficile has been suggested to associate with81.

Experimental Design
In order to test antibodies targeting certain molecules of C. difficile in their ability
to interfere with adherence, target molecules, FliD, HMW SLP, and Cwp84 will be
produced as recombinant proteins from Escherichia coli (E. coli). The recombinant
proteins will be used as immunogens for antibody production in rabbits. Adhesion levels
to Caco-2 BBE cells will be compared between C. difficile pre-treated with pre-immune
serum and serum specific for the target molecules. If the molecules are indeed involved
in C. difficile adhesion to Caco-2 BBE cells, the antibodies should reduce the number of
adherent bacteria compared to naïve serum.

CHAPTER TWO
MATERIALS AND METHODS
C. difficile Culture
C. difficile strain 630 spores were streaked onto 10% sheep blood agar plates
(BAP) (BD Bioscience, Franklin Lakes, New Jersey) and incubated for 48 hours at 36°C
under anaerobic conditions (80% N2, 15% CO2, and 5% H2) in a Bactron IV anaerobic
chamber (Shel Lab, Cornelius, Oregon). A single colony of C. difficile was inoculated
into 20mL anaerobic tryptic soy broth (TSB) (BD Bioscience) and grown overnight (1618 hours) at 36°C anaerobically. Alternatively, a C. difficile colony was inoculated into
brain-heart infusion broth (BHI) (BD Bioscience) and grown overnight.

Isolation of C. difficile Genomic DNA
An overnight culture of C. difficile 630 was prepared in TSB, and the cells were
pelleted by centrifugation at 3,000xG for 10 minutes at 4°C using AllegraTM 6R
centrifuge (Beckman-Coulter, Fullerton, California). Cells were resuspended in 3mL
50mM EDTA solution. Lysozyme, mutanolysin, and lysostaphin were added to 15mg/mL,
1U/mL, and 500μg/mL respectively into the resuspension. RNase A was added to active
concentration of 200μg/mL and the mixture was incubated at 37°C for 1 hour. Proteinase
K and SDS was added to 2.25mg/mL and 1.8% (w/v) respectively, and the mixture was
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incubated at 50°C for another 1 hour. Phenol:chloroform:isoamyl alcohol (3mL) was
added to the mixture, and the mixture was centrifuged at 1,500xG for 5 minutes. The
upper phase was taken and the DNA was precipitated by adding 8mL 100% ethanol and
incubating overnight at -20°C. DNA was pelleted by centrifugation at 3,000xG for 30
minutes at 4°C and the pellet was resuspended in 100μL TE buffer after washing and airdrying. Genomic DNA was stored at 4°C until use.

PCR Amplification of Target Genes
Target coding regions of genes fliD, slpA, and cwp84 were amplified by PCR with
Phusion high-fidelity DNA polymerase (Thermo Scientific, Pittsburg, Pennsylvania)
using specific primers as listed in Table 3. Primers were designed to incorporate BamHI
and XhoI restriction sites to the PCR products. PCR products were separated by 1%
agarose gel electrophoresis and bands corresponding to target size were cut out and
eluted from gel using Wizard® PCR Preps DNA Purification System (Promega, Madison,
Wisconsin). PCR product was then ligated into pGEM® -T Easy vector (Promega) and
subsequently transformed into E. coli DH10B by electroporation using Gibco-BRL CellPorator (Life Technologies, Grand Island, New York). Transformed cells were selected
for resistance against 100μg/mL ampicillin and by blue-white colony screening on LuriaBertani (LB) (BD Bioscience) agar plates overnight at 37°C. Selected clones were
cultured overnight at 37°C in LB broth then stored at -80°C as 20% glycerol stocks.
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Name

Gene

Orientation

fliD
FWD

fliD

Forward

fliD
REV

fliD

Reverse

slpA
FWD

slpA

Forward

slpA
REV

slpA

Reverse

cwp84
FWD

cwp84

Forward

cwp84
REV

cwp84

Reverse

Sequence
5'-ATCG GGA TCC
ATG TCA AGT ATA
AGT CCA GTA AG-3'
5'-ATCG CTC GAG
ATT ACC TTG TGC
TTG TGA GA-3'
5'-TAAG GGA TCC
GCA AAT GAT ACA
A-3'
5'-AGG CTC GAG
CAT ATC TAA TAA
A-3'
5'-TGA GGA TCC
GCA GAA AAC CAT
AAA ACT CTA GAT
G-3'
5'-CCG CTC GAG
AAC TGC TGT TTC
ATA TC-3'

Tm
(°C)

Notes

60.2
Entire coding region
62.4

54.2
HMW SLP coding
region
51.0

60.8
Mature form coding
region
59.4

Table 3. List of primers used in the study. The incorporated restriction site sequences are
noted in bold. The entire fliD coding region was amplified, compared to slpA and cwp84
where only a part of the coding region of interest was amplified. All primers were
ordered from Integrated DNA Technologies (Coralville, Iowa). Bold text indicates the
BamHI and XhoI restriction sites.
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Construction of Expression Plasmids
E. coli clones harboring pGEM® -T Easy constructs with target gene inserts were
streaked onto LB agar plates containing 100μg/mL ampicillin and incubated overnight at
37°C. Single colonies were inoculated into LB broth with 100μg/mL ampicillin for
overnight culture at 37°C. Plasmid DNA from the overnight culture was isolated using
the Wizard® Plus SV Minipreps DNA Purification System (Promega). DNA was stored at
-20°C. pGEM® -T Easy constructs were digested with BamHI and XhoI for 1 hour at
37°C, and pET-21a(+) vector (Merck KGaA, Darmstadt, Germany) was also digested
with BamHI and XhoI for 1 hour. The pET-21a(+) vector was treated with shrimp
alkaline phosphatase (SAP) for 30 minutes at 37°C. Resulting DNA fragments were
separated by 1% agarose gel electrophoresis and bands corresponding to target genes and
pET-21a(+) were cut out, eluted from gel, then subsequently ligated to generate the
expression plasmid constructs. The expression plasmid constructs were transformed into
E. coli DH10B cells by electroporation and colonies were selected by 100μg/mL
ampicillin on LB agar plates after overnight culture at 37°C. Plasmids were extracted
from overnight LB broth culture and digested for 1 hour with BamHI and XhoI at 37°C.
The products were analyzed by 1% agarose gel electrophoresis to confirm the presence of
correct plasmid and insert. Clones harboring correct plasmid construct were cultured
overnight in LB broth and stored at -80°C as 20% glycerol stocks. A list of plasmid
constructs and the parent plasmids can be found in Table 4. All plasmid constructs,
including pGEM® -T Easy and pET-21a(+) constructs were sequenced using ABI Prism
3130 Genetic Analyzer (Life Technologies) to confirm that the cloning was successfully
done in frame. For sequencing, lowered extension temperature (50°C for 4 minutes) was
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used due to the high AT content of target genes, as it has been demonstrated that lowered
extension temperatures in PCR enhances amplification in AT-rich templates112. For
pGEM® -T Easy constructs, T7 promoter-specific and SP6 promoter-specific primers
were used while for pET-21a(+) constructs, the T7 promoter-specific and T7 terminatorspecific primers were used, all ordered from Integrated DNA Technologies.

35

Plasmid
pGEM® -T Easy
pGEM® -T
Easy-fliD
pGEM® -T
Easy-slpA
pGEM® -T
Easy-cwp84
pET-21a(+)
pET-21a(+)fliD
pET-21a(+)slpA
pET-21a(+)cwp84
pRARE2

Description
Plasmid for cloning PCR products,
contains hanging T edges
fliD cloning plasmid construct
slpA cloning plasmid construct

Marker

Ampicillin,
Blue-white

cwp84 cloning plasmid construct
Parent plasmid for expression
fliD expression plasmid construct
slpA expression plasmid construct

Ampicillin

cwp84 expression plasmid construct
Encodes tRNA genes rare in E. coli to
Chloramphenicol
address codon bias

Table 4. List of plasmids used in this study. The pRARE2 plasmid is already contained
by the E. coli Rosetta 2 (DE3) cells by design (Merck KGaA).
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Expression of Target Proteins
The pET-21a(+) expression plasmid constructs were transformed into E. coli
RosettaTM 2 (DE3) cells (Merck KGaA) by electroporation. The RosettaTM 2 strain of E.
coli contains pRARE2, which is a plasmid encoding tRNA genes rare in abundance in E.
coli. This addresses codon bias in E. coli that limits the proteins bacteria can express, and
allows for genes from C. difficile, whose proteins utilize some of these rare codons, to be
expressed more proficiently. The transformed cells were selected with 34μg/mL
chloramphenicol and 200μg/mL ampicillin on LB agar plates. Clones harboring the
plasmid constructs were screened by colony PCR using primers specific for each target
insert (listed in Table 4). Briefly, the PCR template was prepared by picking a single
colony into 100μL dH2O and heating at 100°C for 90 seconds. This sample (1μL) was
used as the template for colony PCR using the Phusion DNA polymerase. PCR products
were analyzed by 1% agarose gel electrophoresis. Clones confirmed to harbor correct
plasmid construct were stored at -80°C as 8% glycerol stocks.
Expression clones were cultured overnight in LB broth containing 34μg/mL
chloramphenicol and 200μg/mL ampicillin. The overnight culture was diluted into fresh
LB broth 1:50 and cultured until OD600nm reached 0.5. At this point, IPTG was added to
0.5mM to induce protein expression for 3 additional hours. Cells were harvested by
centrifugation at 3,000xG for 5 minutes at 4°C, and resuspended in 1mL of 50mM
NaH2PO4, 300mM NaCl solution. Lysozyme was added to 100μg/mL and the mixture
was stored at -80°C to facilitate lysis by freeze-thaw cycles. Thawed lysate was
subsequently cleared by sonication and the soluble and insoluble molecules were
separated by centrifugation at 14,000xG for 15 minutes at 4°C using Sorvall Legend
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Micro 21R centrifuge (Thermo Scientific). The supernatant was labeled “soluble fraction”
and stored at -20°C. The pellet was resuspended in 1mL NaH2PO4, 300mM NaCl
solution containing 6M urea to solubilize the pellet, and this mixture was labeled
“insoluble fraction”. Both fractions were analyzed for target protein expression by 10%
SDS-PAGE followed by Coomassie brilliant blue staining or western blot. For western
blot, the presence of target protein’s N-terminal T7·tag® was detected with biotinylated
anti-T7·tag® mAb (Merck KGaA) at 20ng/mL followed by streptavidin (SAV)
conjugated to HRP at 100ng/mL. Films were developed using Pierce ECL western
blotting substrate (Thermo Scientific).

Purification of Target Proteins
Target proteins expressed in the “soluble fraction” were purified by Ni-NTA
column chromatography using Ni-NTA His·Bind® Resin (Merck KGaA) under native
conditions. Proteins were eluted using increasing concentration of imidazole in buffer
(50mM NaH2PO4 and 300mM NaCl, 20-250mM imidazole, pH 8.0). For proteins
expressed in the “insoluble fraction”, purification was performed in the same way as
those in the “soluble fraction” under denaturing conditions (6M urea). 1mL fractions
collected from column chromatography were analyzed for the presence of target protein
by dot blotting. The dot blot was probed in the same way as the western blot for the
T7·tag® . Select fractions were then analyzed by 10% SDS-PAGE to determine the purity
of the sample. Fractions from initial “soluble fraction” that contained the most purified
target protein were dialyzed into PBS (pH 7.6) and stored at -20°C. For fractions from
initial “insoluble fraction” that contained the most purified target protein, a stepwise
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dialysis was performed to remove urea from solution in order to allow refolding of the
protein. Once dialyzed into buffer without urea (50mM NaH2PO4 and 300mM NaCl), the
fraction was dialyzed in PBS and stored at -20°C.

Immunization of Rabbits
New Zealand White rabbits of at least 3 months of age bred in house were
immunized with target antigens in TiterMax® Gold adjuvant (Sigma-Aldrich, St. Louis,
Missouri) by intramuscular and subcutaneous injections. Rabbits were boosted three
times every two weeks with the same antigen in Freund’s incomplete adjuvant. Blood
was collected every two weeks throughout the immunization procedure to collect serum.
Sera were stored at -20°C. All animal protocols were used as per protocols approved by
the Institutional Animal Care and Use Committee of Loyola University Chicago.

Determination of Antigen-specific Serum Titer
The target antigen-specific titer of each serum collected from rabbits was
determined by enzyme-linked immunosorbance assay (ELISA). Briefly, Costar® 96-well
ELISA plates (Corning, Tewksbury, Massachusetts) were coated with 2μg/mL target
antigen overnight. Coated plates were blocked with PBS containing 2.5% DifcoTM skim
milk (BD Bioscience) for 2 hours at room temperature, then probed with serial dilutions
of antigen-specific serum. Antibodies reactive to specific antigens were detected with
donkey anti-rabbit IgGH+L (heavy and light chains) conjugated to HRP (Jackson
ImmunoResearch, West Grove, Pennsylvania) at 80ng/mL. The plate was then stained
with ABTS staining (0.1M sodium citrate buffer pH 4.5, 1.37mg/mL ABTS, 0.015%
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H2O2) and the absorbance at 405nm using ELx800 Absorbance Microplate Reader
(BioTek® , Winooski, Vermont).

C. difficile S-layer Extraction
Overnight culture of C. difficile 630 or BI-17 was prepared in BHI broth. Cells
were washed in PBS and resuspended in 1mL 200mM glycine buffer, pH 2.2. This
mixture was incubated for 30 minutes at room temperature and subsequently pelleted by
centrifugation at 14,000xG for 15 minutes at 4°C. The resulting supernatant containing
the extracted proteins were dialyzed in PBS and stored at -20°C. The extracted proteins
were analyzed by 8% SDS-PAGE followed by Coomassie brilliant blue staining.

C. difficile Adhesion Interference Assay
Caco-2 BBE cells were grown in Costar® 24-well tissue culture plates (Corning)
until the monolayer reached confluence with high-glucose DMEM (Life Technologies)
with following additives: 10mM HEPES, 1mM pyruvate, 50U/mL penicillin, 50μg/mL
streptomycin, 30μg/mL gentamicin, 550μM L-glutamine, 0.0004% 2-mercaptoethanol,
and 500ng/mL amphotericin B. Once confluent, the monolayer was maintained for three
additional days. One day before the assay, the medium was switched to DMEM
supplemented with only 1.5mM CaCl2. Overnight culture of C. difficile was washed and
resuspended in PBS. 1mL aliquots of C. difficile (diluted to about 6 million colony
forming units (CFU)/mL) were made and each aliquot was incubated with either naïve or
serum specific for target antigens for 15 minutes at 36°C at 1:100 dilution. The antibodyC. difficile mixture was washed once with PBS then resuspended in DMEM with CaCl2.
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Caco-2 BBE monolayer was introduced into the anaerobic chamber and medium was
replaced to anaerobic DMEM with 1.5mM CaCl2, 250μL per well. The pre-incubated C.
difficile mixture was then added to wells 250μL each, achieving about 1.5 x 106 CFU per
well in 500μL total volume (MOI 1, 1:1 ratio of bacteria:host cells). Bacteria were
allowed to adhere for 1 hour at 36°C, then the wells were washed twice with 1mL PBS to
remove non-adherent bacteria. The monolayer was then treated with 1mL PBS containing
1mM EDTA to disrupt tight junctions, and the entire monolayer was dislodged from the
well by vigorous pipetting. A relatively homogenous mixture was obtained for each well
by subsequent vortexing and CFU was determined for each well by plating dilutions onto
BHI agar plates overnight at 36°C. As a control, adherence interference of C. difficile by
pre-incubation of cell monolayer with extracted SLPs, as previously reported in the
literature61, was used. Briefly, the medium for the Caco-2 BBE monolayer in a 24-well
plate was replaced with DMEM containing 1.5mM CaCl2 and 200μg/mL SLP extract,
250μL per well. The cells were incubated under anaerobic conditions at 36°C for 1 hour
before C. difficile in DMEM was added to Caco-2 BBE cells at a MOI of 1. Adherence
was then carried out as outlined above for the antibody assay.

CHAPTER THREE
RESULTS
Cloning of Target Genes into Expression Vector Constructs
From genomic DNA of C. difficile 630, whose genome has been fully sequenced,
slpA (region coding for HMW SLP), fliD (full length), and cwp84 (region coding for
mature form) were amplified by PCR to generate vector constructs for expressing target
proteins. The amplified products were cloned into pET-21a(+) which utilizes a IPTG
inducible system. After obtaining E. coli clones that gained resistance to ampicillin by the
transformation of the pET-21a(+) vector constructs, plasmid DNA was analyzed by
restriction endonuclease digestion with BamHI and XhoI (the sites were introduced into
target genes by PCR) followed by agarose gel electrophoresis. As shown in Figure 5,
digestion of plasmid constructs released DNA bands corresponding to expected sizes of
each target insert, suggesting successful cloning of target genes into the pET-21a(+)
vector. In order to confirm insert as the intended targets and to check for in-frame cloning,
the pET-21a(+) constructs were sequenced at the insertion site. Initial attempts at
sequencing with BigDye® Terminator system (Life Technologies) under standard
conditions repetitively failed to yield product, and so the lowered extension temperature
protocol, as suggested in the literature112 for AT-rich templates, was used to successfully
sequence plasmid DNA at the insertion site. The plasmid constructs were confirmed by
sequencing to be the correct target gene sequences and to be in-frame.
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Figure 5. Restriction digestion analysis of pET-21a(+) expression vector constructs. Each
vector constructs were digested with BamHI and XhoI for 1 hour then analyzed by 1%
agarose gel electrophoresis. In lane 2, a band below the 2.0kb mark can be observed
which corresponds to cwp84 PCR product (about 1.5kb). Also in lane 3, fliD (about 1.5kb)
can be observed below 2.0kb mark. In lane 4, slpA-HMW SLP (about 1.1kb) can be
observed below 2.0kb mark and below the 1.5kb bands shown in lane 2 and 3. In lanes 2,
3, and 4, the pET-21a(+) vector without the insert (about 5.4kb) can be observed between
the 6.5kb and 4.4kb marks. Some other minor bands are present but likely represent
undigested plasmid DNA.
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The correct plasmid constructs were subsequently transformed into E. coli Rosetta
2 (DE3) cells. Because this strain of E. coli does not have endA mutations, plasmid
extraction using standard protocols does not yield quality DNA needed for restriction
digestion analysis (the DH10B strain we used for cloning contains a single point mutation
in the endA gene that inactivates the enzymatic activity of the translated protein). In order
to confirm that the plasmid construct was successfully transformed, colony PCR was
performed instead. As shown in Figure 6, each expression clone harbors their
corresponding target gene insert. Along with selection with ampicillin for the presence of
the pET-21a(+) vector itself, this confirms that correct plasmid constructs were
transformed successfully into their respective expression host.
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Figure 6. Colony PCR of each E. coli clone transformed with pET-21a(+) expression
constructs. Each transformed clone of E. coli was probed with three different specific
primer sets (listed in Table 3) for the presence of target insert. Lanes 5-7 show that the
Cwp84 clone harbors only cwp84; no bands were found using primers for fliD or slpA in
this clone. Likewise, lanes 8-10 show fliD specificity in FliD clone and lanes 11-13 show
the same for HMW SLP clone. No bands are found in lanes 2-4 in which no template was
added to reaction mixture.
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Expression of Target Proteins
E. coli clones harboring the expression plasmid constructs were tested for their
ability to express target proteins. Initially, the expression plasmid constructs were
transformed into E. coli BL21 (DE3) cells (Merck KGaA), a standard strain for
recombinant protein expression. However, only Cwp84 was successfully expressed using
this system, while the induction experiments under various conditions repetitively failed
to produce FliD and HMW SLP. C. difficile genomic DNA is known to be rich in AT
content, and thus quite different from the genomic DNA content of E. coli. The problem,
in the context of recombinant protein production, is that C. difficile proteins utilize
codons that are relatively rare in E. coli since E. coli does not utilize those codons much
for producing its own proteins. This codon bias results in truncated proteins or even early
translational termination which leads to poor or no protein yield. To address the issue of
codon bias, the expression host strain was switched to E. coli Rosetta 2 (DE3) cells,
which possess a pRARE2 plasmid which encodes tRNA genes rare in E. coli, essentially
supplementing the host with rare codons. As shown in Figure 7A, induced lysates of each
of the clones have T7 tagged target proteins which indicate successful expression. The
Cwp84 previously expressed from the BL21 strain was used as a positive control here,
and it can be observed that Cwp84 expression level is much greater in the Rosetta 2 strain.
Thus, subsequent production of Cwp84 was performed using the Rosetta 2 clone instead.
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Figure 7. Analysis of induced E. coli Rosetta 2 (DE3) expression hosts for expressed
proteins. A. Western blot analysis for expressed proteins. Uninduced and induced E. coli
clone lysates were analyzed for the presence of T7·Tag® which is on the N-terminus of
expressed protein construct. HMW SLP (about 45kD), FliD (about 53kD) and Cwp84
(about 50kD) clones show bands at correct respective sizes. The Cwp84 lane is difficult
to visualize due to overpowering signal, but the major banding seems to be ~50kD. SDSPAGE analysis as shown in Figure 7B supports Cwp84 band ~50kD. Uninduced lysates
do not show any bands. (+): control T7 tagged protein. B. SDS-PAGE analysis of
expressed proteins. Induced lysates were separated into insoluble and soluble fractions
and analyzed in separate lanes. For Cwp84, only the insoluble fraction was analyzed. (-):
uninduced sample. (+): induced sample. Box indicates the expected band sizes for each
target proteins.
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Because the purification process for the expressed proteins differ based on the
solubility state of the molecule, a SDS-PAGE analysis was performed for the lysates that
were separated into soluble and insoluble fractions. If the protein is expressed as a
soluble protein, purification is performed under native conditions while if the protein is
insoluble, the expressed protein need to be denatured during purification and
subsequently be refolded into native conditions. As observed from previous work in the
BL21 strain (data not shown), Cwp84 was produced only in the insoluble fraction when
expressed in the Rosetta 2 strain. As for FliD and HMW SLP, the majority of the
expressed proteins are in the soluble fraction while a lesser amount are produced as
insoluble inclusion bodies, indicated in Figure 7B by the darker band staining in the
soluble fraction sample than the insoluble fraction. Therefore, FliD and HMW SLP was
determined to be purified from the soluble fraction using native conditions while Cwp84
was determined to be purified from the insoluble fraction using denaturing conditions.

Purification of Target Proteins
The pET-21a(+) vector construct encodes a C-terminal hexahistidine tag (6x His),
which has affinity to certain metal ions such as Ni2+. Thus, the expressed proteins,
possessing the C-terminal 6x His tag, were purified from E. coli lysates by Ni-NTA
column chromatography. Column fractions (1mL) were collected and each fraction was
tested for the presence of the T7·Tag® by dot blot to determine which fractions contain
the target proteins. One representative dot blot (for FliD) is shown in Figure 8. As shown
in Figure 8, the presence of the fusion tagged proteins in the flow-through fractions
indicate that some expressed target proteins did not bind to column. Only minimal
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amounts of target protein eluted during the wash fractions. Strong signals for the T7·Tag®
can be observed in the first few fractions of the elution fractions, indicating that the
majority of target proteins eluted in those first few fractions.
The dot blot analysis reveals the presence of the target proteins, but it does not
measure the relative purity of the proteins. To determine the degree of protein
purification, SDS-PAGE analysis of select fractions was performed. As shown in Figure
9A, there is a decrease in the number of bands present in the fraction beginning with the
initial, unpurified sample to purified elutions, indicating that the target protein was
selectively purified from the lysate. The same purification procedure was followed for the
other two target proteins HMW SLP and Cwp84, although with Cwp84 purification
followed denaturing conditions containing 6M urea since it was expressed as insoluble
proteins. Figure 9B shows the purified proteins analyzed by SDS-PAGE. Interestingly,
HMW SLP and Cwp84 both show major co-purifying bands. If contaminating E. coli
proteins were present in the purified fractions, the co-purifying bands would be of similar
size across samples since ones that have affinity to Ni2+ would have bound to column.
However, the co-purifying bands are different in HMW SLP and Cwp84 purification,
indicating that degradation products of target proteins during expression are causing these
extra bands. This was later supported by western blot analysis where antibodies raised
against each purified sample did not cross-react against each other, indicating that the copurified bands are not shared between the samples (data not shown).
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Figure 8. Representative dot blot analysis of Ni-NTA fractions (FliD). Flow-through
samples represent fractions collected without imidazole. Wash samples were collected in
the presence of 20mM imidazole (20 Wash), or with 50mM imidazole (50 Wash). Elution
samples were collected in the presence of 250mM imidazole, and the clean samples were
collected with 1M imidazole to elute any remaining proteins. Starting material is the
sample loaded onto the column. The blot was probed for the presence of T7·Tag® . SW:
first fraction collected immediately after switching buffer.
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Figure 9. Purification of target proteins by Ni-NTA column chromatography. A:
Representative SDS-PAGE analysis of select Ni-NTA fractions (FliD). B: SDS-PAGE
analysis of target protein elution fractions containing the most protein. HMW SLP
(~45kD), Cwp84 (~50kD), FliD (~53kD). Gels were all stained with Coomassie Brilliant
Blue.
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Generation of Target Antigen-specific Serum
Purified target proteins were used as immunogens in rabbits to produce antigenspecific antisera. To determine if the rabbits immunized with the antigen indeed
generated antigen-specific antibodies, sera were collected at various points throughout
the immunization protocol and their reactivity to respective immunogens was tested by
ELISA. As shown in Figure 10, there is a significant increase in absorbance in the serum
collected from immunized rabbits compared to naïve serum; in Figure 10, one
representative pre-immune serum (from the FliD-immunized rabbit) is shown, though it
was confirmed that all immunized sera resulted in increased absorbance compared to preimmune serum from other rabbits (data not shown). Also, in other ELISA and western
blot analyses where sera were tested against antigens other than the respective
immunogens, such as anti-FliD antiserum against recombinant HMW SLP, no crossreactivity was observed, indicating that the produced antisera were indeed target antigenspecific (data not shown).
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Figure 10. Production of target antigen-specific antisera from rabbits. Sera from rabbits
were collected after the final booster injection and analyzed for reactivity against
respective antigens by ELISA. Sera were serially diluted 1:2 from 1:1,000 to 1:1,024,000.
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Adherence Interference
To test if antibodies against FliD, HMW SLP, and Cwp84 could block C. difficile
adherence in vitro, an adherence interference assay with Caco-2 BBE cells was
performed. Caco-2 BBE cells are brush-border expressing epithelial cell line of colonic
origin, and serve as an in vitro model for the GI tract epithelial surface to where C.
difficile may initially bind during CDI pathogenesis. Thus, if the target antibodies can
interfere with C. difficile adherence, the adherence of C. difficile pre-incubated with
target-molecule specific antiserum should be decreased compared to those treated with
naïve serum. The adherence interference assay was performed, and no significant
decrease in adherence in C. difficile treated with immune serum compared to naïve serum
was observed as shown in Figure 11. Only one group reached statistically significant
decrease in group pre-treated with all three antisera, but as none of the individual
components achieved significant decrease in C. difficile adherence, it seems likely that
the antibodies targeting FliD, HMW SLP, and Cwp84 do not affect C. difficile adherence
to Caco-2 BBE monolayers.
Interestingly, when Caco-2 BBE monolayers were pre-treated with S-layer
extracts for 1 hour, the subsequent adherence of C. difficile significantly increased as
shown in Figure 11. In the literature, C. difficile SLPs were described as adhesins as the
S-layer extract was shown to decrease C. difficile adherence to Hep-2 cells and also
found to be in proximity of human GI tract sections61. As such, the SLP pre-treatment of
Caco-2 BBE cells were tested essentially as a positive control for this system. However,
in Caco-2 BBE cells which express brush borders, a characteristic of GI tract epithelium,
the SLPs seem to have the opposite effect. This suggests that while SLPs are still
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potential adhesins, they may not serve a major function in C. difficile adherence to Caco2 BBE cells. Similarly, antibodies directed against FliD and Cwp84 also do not affect C.
difficile adherence significantly, indicating that these molecules also may not play a role
in adherence to Caco-2 BBE cells.
It was demonstrated that environmental factors such as divalent cations have
dramatic effects in C. difficile adherence78. Divalent cations are a crucial component of
cellular physiology, thus in vitro culture media are often supplemented with a calcium
source, typically serum. In serum-free media, as used in this C. difficile adherence
interference assay, calcium chloride is added as a source of divalent cation
supplementation. Taking into account the report in which high levels of CaCl2 (up to
25mM) in solution increased C. difficile adherence to Vero cells by 13 to 17-fold78, the
effect of Ca2+ on C. difficile adherence interference in Caco-2 BBE cells was investigated.
When no exogenous calcium was added to the medium, the adherence interference of C.
difficile to Caco-2 cells by target antibodies did not differ significantly from the data
shown in Figure 11 (performed with 1.5mM CaCl2), suggesting that soluble levels of
Ca2+ did not affect adherence interference by target antibodies. Typically, Ca2+ is
supplied to the medium at concentrations below 1.7mM CaCl2 due to its poor solubility
in media containing abundant phosphate and carbonate ions. Nevertheless, 25mM CaCl2
supplementation in DMEM for the C. difficile adherence interference assay was
attempted. While this resulted in significant increase in overall adherence levels (data not
shown), precipitates forming in the medium may have caused this increase in adherence.
Thus, the assay was subsequently performed with only soluble levels of CaCl2 also
because the absence of calcium may affect the monolayer detrimentally.
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Figure 11. C. difficile adherence interference assay with rabbit antisera against target
proteins. % adherence was calculated by dividing the number of CFU C. difficile
recovered by the number of CFU initially added to wells and multiplying by 100. All %
adherence was normalized to C. difficile-only samples. Data pooled from seven different
experiments, normalized to percent adherence of C. difficile alone group in each
experiment. Total sample size (N): C. difficile alone – 17, SLP Pre-treatment – 11, Naïve
serum – 3, α-HMW SLP – 3, α-FliD – 3, α-Cwp84 – 3, Pooled antisera – 11. Statistical
analysis was performed using two-tailed student’s t-test at α=0.05.

CHAPTER FOUR
DISCUSSION
Vaccines and Colonization Resistance
CDI is the major cause of hospital-acquired infectious diarrhea, and its treatment
remains a heavy burden to healthcare systems and a difficult challenge for physicians. As
shown in animal and epidemiological studies, exposure to antibiotics leads to severe
alterations of the gut microbiota, and it is the major risk factor for contracting CDI4. Even
though antibiotics cause CDI, they are also used to treat CDI. Consequently, the
microbiota is still left disrupted for C. difficile to take foothold again and cause recurrent
CDI.
Several new therapies in development seek to address the issue of recurrent
disease. As described in Table 1, new antibiotics have narrower spectrum and cause a
relatively mild alteration of the gut microbiota, and fecal transplantation seeks to restore
the microbiota altered by CDI or antibiotic therapy. Both therapies focus on the
importance of normal gut microbiota, as it provides colonization resistance against C.
difficile. If the microbial balance can be maintained during antibiotic therapy, or be reestablished, recurrent CDI can be prevented through colonization resistance.
Vaccines for CDI have been in development for a while, but most success has
come from targeting TcdA and TcdB, aiming to induce an anti-toxin antibody response in
the host. While antibodies against toxins have been shown in both animal studies and in
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preliminary human trials to have protective effects in CDI, it is suggested that such
response does not prevent colonization with C. difficile11. As such, an individual
successfully vaccinated to generate a neutralizing anti-TcdA/TcdB antibody response
may be asymptomatically colonized, and may still shed infectious spores into the
environment where another individual may contact. If an immune response were
generated that confers colonization resistance against C. difficile in individuals, the
spread of infectious spores could be prevented. Potential for vaccines that could induce
an immune response that confers colonization resistance have thus been investigated in
this study.

C. difficile Adherence to Host GI Tract Mucosa
Bacterial adherence to host gut mucosal surface is a complex process involving
many different factors such as physical mechanics, protein-protein interactions, and
others. For example, both the bacterial cell membrane and the mammalian epithelial cell
membrane is made of a lipid bilayer. The lipid bilayer is kept electrically polarized by the
cells and thus the bacteria must overcome charge-mediated repulsive to get in proximity
with the host cell. Once this barrier is overcome, specific interactions between the host
and the bacteria including adhesin-receptor complexes can mediate tight adhesion
processes. However, the dynamic process that is bacterial adherence to host mucosal
surface is more complex. This is partly due to the nature of the host gut mucosa,
consisting of a heterogeneous population of cells that form the epithelial barrier such as
specialized M cells and goblet cells, immune components that constantly interact with the
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mucosa, and even minor damage that occurs in the epithelium that can cause potentially
significant changes to the mucosa.
In the case of C. difficile, literature suggests that the nature of C. difficile
adherence to host gut mucosa is also complex. While the initial studies suggested that C.
difficile associates with the apical tip of the brush borders on differentiated Caco-2 cells81,
another study suggested that C. difficile binding to Caco-2 cells decrease significantly
upon differentiation of the Caco-2 cells when the brush border expression would
increase82. The latter study suggested that the extracellular matrix is also involved in C.
difficile adherence. In addition, C. difficile flagella can bind to mucus53 which is yet
another surface in the gut mucosa that the bacteria can interact with. Because in vitro cell
line models cannot provide all of the components of the gut mucosal surface, the in vivo
significance of the data on adherence studies are still difficult to interpret in the context
of in vivo pathogenesis.

Models and Adherence Assays
The adherence interference assay with the Caco-2 BBE monolayer seems to
suggest that antibodies against HMW SLP, FliD, and Cwp84 fail to interfere with C.
difficile adherence. This is inconsistent from the published data which suggests that
HMW SLP and FliD work as adhesins in vitro. In the case of Cwp84, the molecule is not
an adhesin but is involved in SlpA processing68, and thus antibody binding may lead to
disrupted S-layer function. While there may be multiple factors that contribute to this
discrepancy, one deviation of this experiment from the literature is the use of a different
cell line. Studies of C. difficile adherence have been initially performed with Caco-2
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cells , as it is a cell line derived from human colonic origin and expresses qualities
resembling enterocytes that line the intestine110. However, published studies of C. difficile
adhesins were not done using Caco-2 cells. FliD was originally identified as an adhesin
using radiolabeled Vero cells, an epithelial cell line of kidney origin that bound to
immobilized FliD53. SLPs were identified as adhesins in studies showing that S-layer
extract mediated adherence interference of C. difficile using Hep-2 cells61, an epithelial
cell line derivative of HeLa cells. At the same time, IgY(major antibody class found in
chicken egg yolk) specific for FliD and Cwp84 was shown to decrease C. difficile
adherence in T84 cells that are metastatic colon cancer cells from the lung72. As for SLPs,
acid-extracted SLPs were also found to be associated with the epithelium of human GI
tract tissue sections61, though no adherence studies with C. difficile were performed with
these tissue sections. Additionally, studies of ΔfilD mutant and ΔfbpA mutant showed
that adherence is increased in the absence of these potential adhesion molecules26, 89
which also makes the role these molecules play in adherence unclear. Along with the data
from Caco-2 BBE epithelial model, the data seem to suggest that antibodies against FliD,
HMW SLP, and Cwp84 can block adherence in some models but not in others. Adding to
this issue, FliD can bind mucus53 while HMW SLP can bind to certain ECM proteins61,
which complicates the matter deciding which binding activity is actually more important
for C. difficile adherence to mucosa. In vitro models of bacterial adherence do not
provide all possible components to which C. difficile may bind, nor can such an approach
easily address the issue of determining which mechanism contributes more than another.
Overall, the failure of the antibodies against FliD, HMW SLP, and Cwp84 to block
adherence in Caco-2 BBE cells highlight the need to recognize that results from one in
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vitro model may not be reproduced in other models. Thus, a different model that better
simulates the in vivo conditions is needed to confirm the adhesion activity of target
molecules and to test if antibodies can block adherence and subsequent colonization.
Some possible models are ex vivo gut mucosal tissue sections to determine if antibodies
block adherence of C. difficile to gastrointestinal mucosa directly and using in vivo
animal model to determine if antibodies can reduce colonization of animal host with C.
difficile.

Alternative Approaches to CDI Vaccines
While the interference of adherence can be a mechanism on which antibodies
against C. difficile surface molecules could protect one from CDI, there are other possible
mechanisms by which the antibodies may protect. Thus, antibodies that do not block C.
difficile adherence may still protect individuals from CDI. One example demonstrating
potential protection employs passive immunization of hamsters using antibodies against
SLPs74. In this study, all hamsters immunized with C. difficile became colonized but
survival was prolonged in immunized hamsters compared to unimmunized hamsters. This
suggested that the antibodies conferred slight resistance to disease in hamsters. While the
level of colonization was not determined in this study, C. difficile pre-incubated with
anti-SLPs antiserum showed enhanced uptake by THP-1 cells, a human phagocytic
monocyte cell line, in vitro. This indicated that the antibodies opsonized C. difficile for
enhanced uptake by THP-1 cells. While protection was modest at best, and it was
unclear if opsonization did play a role in vivo to provide that protection, the study showed
that effective opsonization of C. difficile with antibodies can contribute to protection
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against CDI. Additionally, enhanced uptake of C. difficile can contribute to enhanced
antigen presentation to the adaptive immune system which in turn could enhance
protection. To date, only few opsonization studies with C. difficile have been reported.
Further studies are required to identify which antigens, when targeted by antibodies,
induce opsonization that could enhance host protection.
Many potential targets for vaccine development remain to be tested, including
molecules involved in pathogenesis and those yet to be discovered. As illustrated in
Figure 12, there are multiple mechanisms by which C. difficile interact with the host gut
mucosa that can potentially be targeted by vaccines for protection. The adherence of C.
difficile to gut mucosa, if blocked efficiently by antibodies, could protect one from
colonization. If C. difficile uptake by phagocytic cells can be enhanced by antibodies, it
may also lead to enhanced protection from CDI. It is also known that epithelial cells
harbor receptors that mediate bidirectional transport of antibodies and its antigens across
the epithelium. These mechanisms are capable of transporting in opsonized bacteria for
enhanced immune recognition or transporting invading bacteria out from the lamina
propria to the gut lumen, potentially contributing to protection. There may be additional
mechanisms in which a vaccine could protect such as mechanisms involving complement
activation or other novel mechanisms, but further studies are required to test this
possibility.
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Figure 12. Illustration of known C. difficile-host interaction pathways that have potential
for vaccine development. Blocking of C. difficile interaction with mucus, epithelial
surface, or ECM proteins may interfere with colonization. Alteration of C. difficile uptake
by antigen presenting cells (APC) or transcytosis through the epithelial barrier could
expose bacteria to immune system.
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Concluding Remarks
Prevention and treatment of CDI is a major challenge for healthcare systems.
Because it is initiated by the disruption of the microbiota through antibiotics, CDI
represents a call to develop novel therapeutics that take into consideration a previously
underappreciated aspect of mammalian biology, the microbiota. Vaccines have the
potential to prevent the spread of CDI by preventing colonization that can last an
individual’s lifetime given an effective immunization strategy. Many candidate molecules
have been identified for vaccine development to prevent CDI, but the complexity of C.
difficile interaction with the host gut mucosal environment presents a challenge to
extrapolate the current in vitro findings for in vivo significance. In this work, antibodies
against FliD, HMW SLP, and Cwp84, molecules suggested in the literature to be
involved in C. difficile adherence, were tested for their ability to reduce C. difficile
adherence to Caco-2 BBE cell line, a model for gut intestinal epithelium not described
previously in studies of C. difficile adherence interference. The antibodies failed to
significantly reduce C. difficile adherence in this model which suggest that antibodymediated adherence inhibition may be dependent upon different assay conditions. There
are many more vaccine candidates to be tested and discovered including those that may
confer protection through mechanisms not involving adherence. The data here highlight a
need to study different, alternative models of C. difficile interactions with host mucosa in
order to identify and test vaccine potential of molecules and mechanisms yet to be
discovered.

REFERENCES
1. Bartlett JG. Historical Perspectives on Studies of Clostridium difficile and C.
difficile Infection. Clinical Infectious Diseases. 2008;46:S4-11.
2. Panessa-Warren BJ, Tortora GT, and Warren JB. Exosporial membrane
plasticity of Clostridium sporogenes and Clostridium difficile. Tissue and Cell.
1997;29(4):449-463.
3. Rupnik M, Wilcox MH, and Gerding DN. Clostridium difficile infection: new
developments in epidemiology and pathogenesis. Nature Reviews Microbiology.
2009;7:526-536
4. Hensgens MPM, Goorhuis A, Dekkers OM, and Kuijper EJ. Time interval of
increased risk for Clostridium difficile infection after exposure to antibiotics.
Journal of Antimicrobial Chemotherapy. 2012;67:742-748.
5. McDonald LC, Lessa F, Sievert D, Wise M, Herrera R, Gould C, Malpiedi P,
Dudeck M, Srinivasan A, Fridkin S, and Cardo D. Vital Signs: Preventing
Clostridium difficile Infections. Centers for Disease Control and Prevention
Morbidity and Mortality Weekly Report. 2012;61:1-5.
6. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin
J, and Wilcox MH. Clinical Practice Guidelines for Clostridium difficile
Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of
America (SHEA) and the Infectious Diseases Society of America (IDSA).
Infection Control and Hospital Epidemiology. 2010;31(5):431-455.
7. Venugopal AA and Johnson S. Fidaxomicin: A Novel Macrolytic Antibiotic
Approved for Treatment of Clostridium difficile Infection. Clinical Infectious
Diseases. 2012;54(4):568-574.
8. Merrigan MM, Sambol SP, Johnson S, and Gerding DN. New approach to the
management of Clostridium difficile infection: colonization with non-toxigenic C.
difficile during daily ampicillin or ceftriaxone administration. International
Journal of Antimicrobial Agents. 2009;33(S1):S46-50.
9. Fitzpatrick LR, Small JS, Greene WH, Karpa KD, and Keller D. Bacillus
coagulans GBI-30 (BC30) improves indices of Clostridium difficile-Induced
colitis in mice. Gut Pathogens. 2011;3(16):1-9.
64

65
10. Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, De Vos WM,
Visser CE, Kuijper EJ, Bartelsman JFWM, Tijssen JGP, Speelman P,
Dijkgraaf MGW, and Keller JJ. Duodenal Infusion of Donor Feces for
Recurrent Clostridium difficile. The New England Journal of Medicine.
2013;368(5):407-415.
11. Siddiqui F, O’Connor JR, Nagaro K, Cheknis A, Sambol SP, Vendantam G,
Gerding DN, and Johnson S. Vaccination With Parenteral Toxoid B Protects
Hamsters Against Lethal Challenge With Toxin A-Negative and Toxin B-Positive
Clostridium difficile but Does Not Prevent Colonization. The Journal of Infectious
Diseases. 2012;205:128-133.
12. Kotloff KL, Wasserman SS, Losonsky GA, Thomas Jr. W, Nichols R,
Edelman R, Bridwell M, and Monath TP. Safety and Immunogenicity of
Increasing Doses of a Clostridium difficile Toxoid Vaccine Administered to
Healthy Adults. Infection and Immunity. 2001;69(2):988-995.
13. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S,
Giannasca PJ, Monath TP, and Kelly CP. Clostridium difficile Vaccine and
Serum Immunoglobulin G Antibody Response to Toxin A. Infection and
Immunity. 2003;71(3):1608-1610.
14. Hall IC and O’Toole E. Intestinal Flora in New-Born Infants with a Description
of a New Pathogenic Anaerobe, Bacillus difficilis. American Journal of Diseases
of Children. 1935;49(2):390-402.
15. Bartlett JG, Moon N, Chang TW, Taylor N, and Underdone AB. Role of
Clostridium difficile in Antibiotic-Associated Pseudomembranous Colitis.
Gastroenterology. 1978;75(5):778-782.
16. Mitchell MJ, Laughon BE, and Lin S. Biochemical studies on the effect of
Clostridium difficile toxin B on actin in vivo and in vitro. Infection and Immunity.
1987;55(7):1610-1615.
17. Just I, Selzer J, Eichel-Streiber CV, and Aktories K. The Low Molecular Mass
GTP-binding Protein Rho is Affected by Toxin A from Clostridium difficile.
Journal of Clinical Investigation. 1995;95(3):1026-1031.
18. Voth DE and Ballard JD. Clostridium difficile Toxins: Mechanism of Action
and Role in Disease. Clinical Microbiology Reviews. 2005;18(2):247-263.
19. Ricciardi R, Rothenberger DA, Madoff RD, and Baxter NN. Increasing
Prevalence and Severity of Clostridium difficile Colitis in Hospitalized Patients in
the United States. Archives of Surgery. 2007;142(7):624-631.

66
20. Badger VO, Ledeboer NA, Graham MB, and Edmiston Jr. CE. Clostridium
difficile: Epidemiology, Pathogenesis, Management, and Prevention of a
Recalcitrant Healthcare-Associated Pathogen. Journal of Parenteral and Enteral
Nutrition. 2012;36(6):645-662.
21. McDonald LC, Owings M, and Jernigan DB. Clostridium difficile Infection in
Patients Discharged from US Short-stay Hospitals, 1996-2003. Emerging
Infectious Diseases. 2006;12(3):409-415.
22. McDonald LC, Killgore GE, Thompson A, Owens Jr. RC, Kazakova SV,
Sambol SP, Johnson S, and Gerding DN. An Epidemic, Toxin Gene-Variant
Strain of Clostridium difficile. The New England Journal of Medicine.
2005;353(23):2433-2441.
23. Carter GP, Douce GR, Govind R, Howarth PM, Mackin KE, Spencer J,
Buckley AM, Antunes A, Kotsanas D, Jenkin GA, Dupuy B, Rood JI, and
Lyras D. The Anti-Sigma Factor TcdC Modulates Hypervirulence in an Epidemic
BI/NAP1/027 Clinical Isolate of Clostridium difficile. PLoS Pathogens.
2011;7(10):1-11.
24. Van Leeuwen HC, Bakker D, Steindel P, Kuijper EJ, and Corver J.
Clostridium difficile TcdC protein binds four-stranded G-quadruplex structures.
Nucleic Acids Research. 2013;41(4):2382-2393.
25. Cartman ST, Kelly ML, Heeg D, Heap JT, and Minton NP. Precise
Manipulation of the Clostridium difficile Chromosome Reveals a Lack of
Association between the tcdC Genotype and Toxin Production. Applied and
Environmental Microbiology. 2012;78(13):4683-4690.
26. Dingle TC, Mulvey GL, and Armstrong GD. Mutagenic Analysis of the
Clostridium difficile Flagellar Proteins, FliC and FliD, and Their Contribution to
Virulence in Hamsters. Infection and Immunity. 2011;79(10):4061-4067.
27. Aubry A, Hussack G, Chen W, KuoLee R, Twine SM, Fulton KM, Foote S,
Carrillo CD, Tanha J, and Logan SM. Modulation of Toxin Production by the
Flagellar Regulon in Clostridium difficile. Infection and Immunity.
2012;80(10):3521-3532.
28. Chilton CH, Freeman J, Crowther GS, Todhunter SL, Nicholson S, and
Wilcox MH. Co-amoxiclav induces proliferation and cytotoxin production of
Clostridium difficile ribotype 027 in a human gut model. Journal of Antimicrobial
Chemotherapy. 2012;67(4):951-954.
29. McGlone SM, Bailey RR, Zimmer SM, Popovich MJ, Tian Y, Ufberg P,
Muder RR, and Lee BY. The economic burden of Clostridium difficile. Clinical
Microbiology and Infection. 2012;18(3):282-289.

67
30. Change TW, Bartlett JG, Gorbach SL, and Onderdonk AB. Clindamycininduced enterocolitis in hamsters as a model of pseudomembranous colitis in
patients. Infection and Immunity. 1978;20(2):526-529.
31. Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding
DN, and Kelly CP. A Mouse Model of Clostridium difficile-Associated Disease.
Gastroenterology. 2008;135(6):1984-1992.
32. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, Ubeda
C, Xavier J, and Pamer EG. Profound Alterations of Intestinal Microbiota
following a Single Dose of Clindamycin Results in Sustained Susceptibility to
Clostridium difficile-Induced Colitis. Infection and Immunity. 2012;80(1):62-73.
33. O’Neill GL, Beaman MH, and Riley TV. Relapse versus reinfection with
Clostridium difficile. Epidemiology and Infection. 1991;107(3):627-635.
34. Freeman J, Baines SD, Jabes D, and Wilcox MH. Comparison of the efficacy
of ramoplanin and vancomycin in both in vitro and in vivo models of
clindamycin-induced Clostridium difficile infection. Journal of Antimicrobial
Chemotherapy. 2005;56(4):717-725.
35. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach
S, Sears P, and Shue YK. Fidaxomicin versus Vancomycin for Clostridium
difficile Infection. The New England Journal of Medicine. 2011;364(5):422-431.
36. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J,
and Louie T. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less
alteration to the bowel microbiota of Clostridium difficile-infected patients than
does vancomycin. Microbiology. 2010;156(11):3354-3359.
37. Gaboriau-Routhiau V, Rakotobe S, Lécuyer E, Mulder I, Lan A, Bridonneau
C, Rochet V, Pisi A, De Paepe M, Brandi G, Eberi G, Snel J, Kelly D, and
Cerf-Benusussan N. The Key Role of Segmented Filamentous Bacteria in the
Coordinated Maturation of Gut Helper T Cell Responses. Immunity.
2009;31(4):677-689.
38. Macpherson AJ and Uhr T. Induction of Protective IgA by Intestinal Dendritic
Cells Carrying Commensal Bacteria. Science. 2004;303(5664):1662-1665.
39. Fanning S, Hall LJ, Cronin M, Zomer A, MacSharry J, Goulding D,
Motherway MO, Shanahan F, Nally K, Dougan G, and Van Sinderen D.
Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction
through immune modulation and pathogen protection. Proceedings of the
National Academy of Sciences of the United States of America. 2012;109(6):21082113.

68
40. Lundell AC, Bjӧrnsson V, Ljung A, Ceder M, Johansen S, Lindhagen G,
Tӧrnhage CJ, Adlerberth I, Wold AE, and Rudin A. Infant B Cell Memory
Differentiation and Early Gut Bacterial Colonization. Journal of Immunology.
2012;188(9):4315-4322.
41. Duerkop BA, Vaishnava S, and Hooper LV. Immune Responses to the
Microbiota at the Intestinal Mucosal Surface. Immunity. 2009;31(3):368-376.
42. D’Arienzo R, Maurano F, Mazzarella G, Luongo D, Stefanile R, Ricca E, and
Rossi M. Bacillus subtilis spores reduce susceptibility to Citrobacter rodentiummediated enteropathy in a mouse model. Research in Microbiology.
2006;157(9):891-897.
43. Hasegawa M, Kamada N, Jiao Y, Liu MZ, Núñez G, and Inohara N.
Protective Role of Commensals against Clostridium difficile Infection via an IL1β-Mediated Positive-Feedback Loop. Journal of Immunology.
2012;186(6):3085-3091.
44. Gerding DN. Clostridium difficile Infection Prevention: Biotherapeutics,
Immunologics, and Vaccines. Discovery Medicine. 2012;13(68):75-83.
45. Torres JF, Lyerly DM, Hill JE, and Monath TP. Evaluation of FormalinInactivated Clostridium difficile Vaccines Administered by Parenteral and
Mucosal Routes of Immunization in Hamsters. Infection and Immunity.
1995;63(12):4619-4627.
46. Kyne L, Warny M, Qamar A, and Kelly CP. Asymptomatic Carriage of
Clostridium difficile and Serum Levels of IgG Antibody Against Toxin A. The
New England Journal of Medicine. 2000;342(6):390-397.
47. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K,
Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM,
and Thomas Jr. WD. Human Monoclonal Antibodies Directed against Toxins A
and B Prevent Clostridium difficile-Induced Mortality in Hamsters. Infection and
Immunity. 2006;74(11):6339-6347.
48. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G,
Thomas Jr. WD, Leney M, Sloan S, Hay CA, Ambrosino DM. Treatment with
Monoclonal Antibodies against Clostridium difficile Toxins. The New England
Journal of Medicine. 2010;362(3):197-205.
49. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, and
Flyer DC. A novel fusion protein containing the receptor binding domains of C.
difficile toxin A and toxin B elicits protective immunity against lethal toxin and
spore challenge in preclinical efficacy models. Vaccine. 2012;30(28):4249-4258.

69
50. Stocker BAD and Campbell JC. The Effect of Non-Lethal Deflagellation on
Bacterial Motility and Observations on Flagellar Regeneration. Journal of
General Microbiology. 1959;20(3):670-685.
51. Kim JS, Chang JH, Chung SI, and Yum JS. Molecular Cloning and
Characterization of the Helicobacter pylori fliD Gene, an Essential Factor in
Flagellar Structure and Motility. Journal of Bacteriology. 1999;181(22):69696976.
52. Arora SK, Ritchings BW, Almira EC, Lory S, and Ramphal R. The
Pseudomonas aeruginosa Flagellar Cap Protein, FliD, Is Responsible for Mucin
Adhesion. Infection and Immunity. 1998;66(3):1000-1007.
53. Tasteyre A, Barc M, Collignon A, Boureau H, and Karjalainen T. Role of
FliC and FliD Flagellar Proteins of Clostridium difficile in Adherence and Gut
Colonization. Infection and Immunity. 2001;69(12):7937-7940.
54. Péchiné S, Gleizes A, Janoir C, Gorges-Kergot R, Barc M, Delmée M, and
Collignon A. Immunological properties of surface proteins of Clostridium
difficile. Journal of Medical Microbiology. 2005;54(2):193-196.
55. Tasteyre A, Karjalainen T, Avesani V, Delmée M, Collignon A, Bourlioux P,
and Barc MC. Phenotypic and Genotypic Diversity of the Flagellin Gene (fliC)
among Clostridium difficile Isolates from Different Serogroups. Journal of
Clinical Microbiology. 2000;38(9):3179-3186.
56. Tasteyre A, Karjalainen T, Avesani V, Delmée M, Collignon A, Bourlioux P,
and Barc MC. Molecular Characterization of fliD Gene Encoding Flagellar Cap
and Its Expression among Clostridium difficile Isolates from Different Serogroups.
Journal of Clinical Microbiology. 2001;39(3):1178-1183.
57. Takeoka A, Takumi K, Koga T, and Kawata T. Purification and
characterization of S layer proteins from Clostridium difficile GAI 0714. Journal
of General Microbiology. 1991;137
58. Sleytr UB and Beveridge TJ. Bacterial S-layers. Trends in Microbiology.
1999;7(6):253-260.
59. Calabi E, Ward S, Wren B, Paxton T, Panico M, Morris H, Dell A, Dougan G,
and Fairweather N. Molecular characterization of the surface layer proteins from
Clostridium difficile. Molecular Microbiology. 2001;40(5):1187-1199.
60. Fagan RP, Albessa-Jové D, Qazi O, Svergun DI, Brown KA, and Fairweather
NF. Structural insights into the molecular organization of the S-layer from
Clostridium difficile. Molecular Microbiology. 2009;71(5):1308-1322.

70
61. Calabi E, Calabi F, Phillips AD, and Fairweather NF. Binding of Clostridium
difficile Surface Layer Proteins to Gastrointestinal Tissues. Infection and
Immunity. 2002;70(10):5770-5778.
62. Chen TR. Re-evaluation of HeLa, HeLa S3, and HEp-2 karyotypes. Cytogenetics
and Cell Genetics. 1988;48(1):19-24.
63. Wright A, Drudy D, Kyne L, Brown K, and Fairweather NF. Immunoreactive
cell wall proteins of Clostridium difficile identified by human sera. Journal of
Medical Microbiology. 2008;57(6):750-756.
64. Karjalainen T, Waligora-Dupriet AJ, Cerquetti M, Spigaglia P, Maggioni A,
Mauri P, and Mastrantonio P. Molecular and Genomic Analysis of Genes
Encoding Surface-Anchored Proteins from Clostridium difficile. Infection and
Immunity. 2001;69(5):3442-3446.
65. Fagan RP, Janoir C, Collignon A, Mastrantonio P, Poxton IR, and
Fairweather NF. A proposed nomenclature for cell wall proteins of Clostridium
difficile. Journal of Medical Microbiology. 2011;60(8):1225-1228.
66. Dang THT, De la Riva L, Fagan RP, Storck EM, Heal WP, Janoir C,
Fairweather NF, and Tate EW. Chemical Probes of Surface Layer Biogenesis
in Clostridium difficile. ACS Chemical Biology. 2010;5(3):279-285.
67. Kirby JM, Ahern H, Roberts AK, Kumar V, Freeman Z, Acharya KR, and
Shone CC. Cwp84, a Surface-associated Cysteine Protease, Plays a Role in the
Maturation of the Surface Layer of Clostridium difficile. Journal of Biological
Chemistry. 2009;284(50):34666-34673.
68. De la Riva L, Willing SE, Tate EW, and Fairweather NF. Roles of Cysteine
Proteases Cwp84 and Cwp13 in Biogenesis of the Cell Wall of Clostridium
difficile. Journal of Bacteriology. 2011;193(13):3276-3285.
69. Chapéton-Montes D, Candela T, Collignon A, and Janoir C. Localization of
the Clostridium difficile Cysteine Protease Cwp84 and Insights into Its Maturation
Process. Journal of Bacteriology. 2011;193(19):5314-5321.
70. Janoir C, Péchiné S, Grosdidier C, and Collignon A. Cwp84, a SurfaceAssociated Protein of Clostridium difficile, Is a Cysteine Protease with Degrading
Activity on Extracellular Matrix Proteins. Journal of Bacteriology.
2007;189(20):7174-7180.
71. Péchiné S, Janoir C, Boureau H, Gleizes A, Tsapis N, Hoys S, Fattal E, and
Collignon A. Diminished intestinal colonization by Clostridium difficile and
immune response in mice after mucosal immunization with surface proteins of
Clostridium difficile. Vaccine. 2007;25(20):3946-3954.

71
72. Péchiné S, Denéve C, Le Monnier A, Hoys S, Janoir C, and Collignon A.
Immunization of hamsters against Clostridium difficile infection using the Cwp84
protease as an antigen. FEMS Immunology and Medical Microbiology.
2011;63(1):73-81.
73. Mulvey GL, Dingle TC, Fang L, Strecker J, and Armstrong GD. Therapeutic
potential of egg yolk antibodies for treating Clostridium difficile infection.
Journal of Medical Microbiology. 2011;60(8):1181-1187.
74. O’Brien JB, McCabe MS, Athié-Morales V, McDonald GSA, Ní Eidhin DB,
Kelleher DP. Passive immunisation of hamsters against Clostridium difficile
infection using antibodies to surface layer proteins. FEMS Microbiology Letters.
2005;246(2):199-205.
75. Heap JT, Pennington OJ, Cartman ST, Carter GP, and Minton NP. The
ClosTron: A universal gene knock-out system for the genus Clostridium. Journal
of Microbiological Methods. 2007;70(3):452-464.
76. Waligora AJ, Hennequin C, Mullany P, Bourlioux P, Collignon A, and
Karjalainen T. Characterization of a Cell Surface Protein of Clostridium difficile
with Adhesive Properties. Infection and Immunity. 2001;69(4):2144-2153.
77. Hennequin C, Porcheray F, Waligora-Dupriet AJ, Collignon A, Barc MC,
Bourlioux P, and Karjalainen T. GroEL (Hsp60) of Clostridium difficile is
involved in cell adherence. Microbiology. 2001;147(1):87-96.
78. Waligora AJ, Barc MC, Bourlioux P, Collignon A, Karjalainen T.
Clostridium difficile Cell Attachment Is Modified by Environmental Factors.
Applied and Environmental Microbiology. 1999;65(9):4234-4238.
79. Hundsberger T, Braun V, Weidmann M, Leuker P, Sauerborn M, and
Eichel-Streiber CV. Transcription analysis of the genes tcdA-E of the
pathogenicity locus of Clostridium difficile. European Journal of Biochemistry.
1997;244(3):735-742.
80. Denéve C, Deloménie C, Barc MC, Collignon A, and Janoir C. Antibiotics
involved in Clostridium difficile-associated disease increase colonization factor
gene expression. Journal of Medical Microbiology. 2008;57(6)732-738.
81. Eveillard M, Fourel V, Barc MC, Kernéis S, Coconnier MH, Karjalainen T,
Bourlioux P, and Servin AL. Identification and characterization of adhesive
factors of Clostridium difficile involved in adhesion to human colonic enterocytelike Caco-2 and mucus-secreting HT29 cells in culture. Molecular Microbiology
1993;7(3):371-381.

72
82. Cerquetti M, Serafino A, Sebastianelli A, and Mastrantonio P. Binding of
Clostridium difficile to Caco-2 epithelial cell line and to extracellular matrix
proteins. FEMS Immunology and Medical Microbiology. 2002;32(3):211-218.
83. Bornstein P and Ash JF. Cell surface-associated structural proteins in
connective tissue cells. Proceedings of the National Academy of Sciences of the
United States of America. 1977;74(6):2480-2484.
84. Van der Flier M, Chhun N, Wizemann TM, Min J, McCarthy JB, and
Toumanen EI. Adherence of Streptococcus pneumoniae to Immobilized
Fibronectin. Infection and Immunity. 1995;63(11):4317-4322.
85. Courtney HS, Ofek I, Simpson WA, Hasty DL, and Beachey EH. Binding of
Streptococcus pyogenes to Soluble and Insoluble Fibronectin. Infection and
Immunity. 1986;53(3):454-459.
86. Courtney HS, Li Y, Dale JB, and Hasty DL. Cloning, Sequencing, and
Expression of a Fibronectin/Fibrinogen-Binding Protein from Group A
Streptococci. Infection and Immunity. 1994;62(9):3937-3946.
87. Hennequin C, Janoir C, Barc MC, Collignon A, and Karjalainen T.
Identification and characterization of a fibronectin-binding protein from
Clostridium difficile. Microbiology. 2003;149(10):2779-2787.
88. Lin YP, Kuo CJ, Koleci X, McDonough SP, and Chang YF. Manganese Binds
to Clostridium difficile Fpb68 and Is Essential for Fibronectin Binding. The
Journal of Biological Chemistry. 2011;286(5):3957-3969.
89. Barketi-Klai A, Hoys S, Lambert-Bordes S, Collignon A, and Kansau I. Role
of fibronectin-binding protein A in Clostridium difficile intestinal colonization.
Journal of Medical Microbiology. 2011;60(8):1155-1161.
90. Perelle S, Gibert M, Bourlioux P, Corthier G, and Popoff MR. Production of a
Complete Binary Toxin (Actin-Specific ADP-Ribosyltransferase) by Clostridium
difficile CD196. Infection and Immunity. 1997;65(4):1402-1407.
91. Stiles BG, Wigelsworth DJ, Popoff MR, and Barth H. Clostridial binary toxins:
iota and C2 family portraits. Frontiers in Cellular and Infection Microbiology.
2011;1(11):1-14.
92. Ponta H, Sherman L, Herrlich PA. CD44: From Adhesion Molecules to
Signaling Regulators. Nature Reviews Molecular Cell Biology. 2003;4(1):33-45.
93. Wigelsworth DJ, Ruthel G, Schnell L, Herrlich P, Blonder J, Veenstra TD,
Carman RJ, Wilkins TD, Van Nhieu GT, Pauillac S, Gibert M, Sauvonnet N,
Stiles BG, Popoff MR, and Barth H. CD44 Promotes Intoxication by the
Clostridial Iota-Family Toxins. PLoS One. 2012;7(12):1-9.

73
94. Papatheodorou P, Hornuss D, Nӧlke T, Hemmasi S, Castonguay J, Picchianti
M, and Aktories K. Clostridium difficile Binary Toxin CDT Induces Clustering
of the Lipolysis-Stimulated Lipoprotein Receptor into Lipid Rafts. mBio.
2013;4(3):1-8.
95. Schwan C, Stecher B, Tzivelekidis T, Van Ham M, Rohde M, Hardt WD,
Wehland J, and Aktories K. Clostridium difficile Toxin CDT Induces Formation
of Microtubule-Based Protrusions and Increases Adherence of Bacteria. PLoS
Pathogens. 2009;5(10):1-14.
96. Hall-Stoodley L, Costerton JW, and Stoodley P. Bacterial Biofilms: From the
Natural Environment to Infectious Diseases. Nature Reviews Microbiology.
2004;2(2):95-108.
97. Donelli G, Vuotto C, Cardines R, and Mastrantonio P. Biofilm-growing
intestinal anaerobic bacteria. FEMS Immunology and Medical Microbiology.
2012;65(2):318-325.
98. Ð apa T, Leuzzi R, Ng YK, Baban ST, Adamo R, Kuehne SA, Scarselli M,
Minton NP, Serruto D, and Unnikrishnan M. Multiple Factors Modulate
Biofilm Formation by the Anaerobic Pathogen Clostridium difficile. Journal of
Bacteriology. 2013;195(3):545-555.
99. Fujita M and Losick R. Evidence that entry into sporulation in Bacillus subtilis
is governed by a gradual increase in the level and activity of the master regulator
Spo0A. Genes and Development. 2005;19(18):2236-2244.
100. Deakin LJ, Clare S, Fagan RP, Dawson LF, Pickard DJ, West MR, Wren
BW, Fairweather NF, Dougan G, and Lawley TD. The Clostridium difficile
spo0A Gene Is a Persistence and Transmission Factor. Infection and Immunity.
2012;80(8):2704-2711.
101. Paredes-Sabja D and Sarker MR. Adherence of Clostridium difficile spores to
Caco-2 cells in culture. Journal of Medical Microbiology. 2012;61(9):1208-1218.
102. Reynolds CB, Emerson JE, De la Riva L, Fagan RP, and Fairweather NF.
The Clostridium difficile Cell Wall Protein CwpV is Antigenically Variable
between Strains, but Exhibits Conserved Aggregation-Promoting Function. PLoS
Pathogens. 2011;7(4):1-14.
103. Dembek M, Reynolds CB, and Fairweather NF. The Clostridium difficile cell
wall protein CwpV undergoes enzyme-independent intramolecular
autoproteolysis. The Journal of Biological Chemistry. 2012;287(2):1538-1544.
104. Kuboniwa M, Amano A, Hashino E, Yamamoto Y, Inaba H, Hamada N,
Nakayama K, Tribble GD, Lamont RJ, and Shizukuishi S. Distinct roles of

74
long/short fimbriae and gingipains in homotypic biofilm development by
Porphyromonas gingivalis. BMC Microbiology. 2009;9(105):1-13.
105. Emerson JE, Reynolds CB, Fagan RP, Shaw HA, Goulding D, and
Fairweather NF. A novel genetic switch controls phase variable expression of
CwpV, a Clostridium difficile cell wall protein. Molecular Microbiology.
2009;74(3):541-556.
106. Tulli L, Marchi S, Petracca R, Shaw HA, Fairweather NF, Scarselli M,
Soriani M, and Leuzzi R. CbpA: a novel surface exposed adhesin of Clostridium
difficile targeting human collagen [published ahead of print]. Cellular
Microbiology. 2013.
107. Holmgren J and Czerkinsky C. Mucosal Immunity and Vaccines. Nature
Medicine. 2005;11(4):S45-S53.
108. Holmgren J and Svernnerholm AM. Vaccines against mucosal infections.
Current Opinion in Immunology. 2012;24(3):343-353.
109. Frazão N, Brito-Avȏ A, Simas C, Saldanha J, Mato R, Nunes S, Sousa NG,
Carriço JA, Almeida JS, Santos-Sanches I, and De Lencastre H. Effect of the
Seven-Valent Conjugate Pneumococcal Vaccine on Carriage and Drug Resistance
of Streptococcus pneumoniae in Healthy Children Attending Day-Care Centers in
Lisbon. The Pediatric Infectious Disease Journal. 2005;24(3):243-252.
110. Peterson MD and Mooseker MS. Characterization of the enterocyte-like brush
border cytoskeleton of the C2BBe clones of the human intestinal cell line, Caco-2.
Journal of Cell Science. 1992;102(3):581-600.
111. Čepeljnik T, Lah B, Narat M, and Marinšek-Logar R. Adaptation of Adhesion
Test Using Caco-2 Cells for Anaerobic Bacterium Pseudobutyrivibrio
xylanivorans, a Probiotic Candidate.
112. Su XZ, Wu Y, Sifri CD, and Wellems TE. Reduced extension temperatures
required for PCR amplification of extremely A+T-rich DNA. Nucleic Acids
Research. 1996;24(8):1574-1575.
113. O’Brien JA, Lahue BJ, Caro JJ, and Davidson DM. The emerging infectious
challenge of Clostridium difficile-associated disease in Massachusetts hospitals:
clinical and economic consequences. Infection Control and Hospital
Epidemiology. 2007;28(11):1219-1227.

VITA
Wonbeom “Won” Paik was born in 1989 and raised in Seoul, Republic of Korea.
In 2000, he came to United States where he attended middle and high school in Chicago
and in Aurora, Illinois. He went on to DePaul University to earn his Bachelor of Science
degree cum laude in biotechnology, minoring in sociology. During his undergraduate
studies, he was introduced to research by studying chromosomal congression in female
Drosophila melanogaster during meiosis I in the lab of Dr. William Gilliland. Also, he
studied the increased risk of osteoporosis in HIV patients at an internship through the
Department of Sociology at DePaul. He also participated in the university honor’s
program throughout his undergraduate career.
After graduation in 2007, he joined the Master’s program in Infectious Disease
and Immunology at Loyola University Chicago. He then joined the laboratory of Dr.
Katherine Knight and studied Clostridium difficile infection and vaccine development
with the guidance of Dr. Knight and Dr. Dale Gerding. After the completion of his
Master’s degree, Won will be joining medical school at Stritch School of Medicine in
Maywood, Illinois.

75

